Breast Cancer Basic Facts

What is breast cancer?
Cancer is a group of diseases that cause cells in the body to change and grow out of control. Most types of cancer cells eventually form a lump or mass called a tumor, and are named after the part of the body where the tumor originates.

Breast cancer begins in the breast tissue that is made up of glands for milk production, called lobules, and the ducts that connect the lobules to the nipple. The remainder of the breast is made up of fatty, connective, and lymphatic tissues.

Breast cancer typically is detected either during a screening examination, before symptoms have developed, or after symptoms have developed, when a woman feels a lump. Most masses seen on a mammogram and most breast lumps turn out to be benign; that is, they are not cancerous, do not grow uncontrollably or spread, and are not life-threatening. When cancer is suspected based on clinical breast exam or breast imaging, microscopic analysis of breast tissue is necessary for a definitive diagnosis and to determine the extent of spread (in situ or invasive) and characterize the pattern of the disease. The tissue for microscopic analysis can be obtained via a needle or surgical biopsy. Selection of the type of biopsy is based on individual patient clinical factors, availability of particular biopsy devices, and resources.

In situ
- Ductal carcinoma in situ (DCIS) is a spectrum of abnormal breast changes that start in the cells lining the breast ducts. DCIS is considered a noninvasive form of breast cancer because the abnormal cells have not grown beyond the layer of cells where they originated. It is the most common type of in situ breast cancer, accounting for about 83% of in situ cases diagnosed during 2006-2010. DCIS may or may not progress to invasive cancer; in fact, some of these tumors grow so slowly that even without treatment they would not affect a woman’s health. Studies suggest that about one-third, and possibly more, of DCIS cases will progress to invasive cancer if left untreated. Identifying subtypes of DCIS that are most likely to recur or progress to invasive cancer is an active area of research.
- Lobular carcinoma in situ (LCIS, also known as lobular neoplasia) is not a true cancer or precancer, but an indicator of increased risk for developing invasive cancer. LCIS is much less common than DCIS, accounting for about 12% of female in situ breast cancers diagnosed during 2006-2010. See page 12 for more information on LCIS.
- Other in situ breast cancers have characteristics of both ductal and lobular carcinomas or have unknown origins.

Invasive
Most breast cancers are invasive, or infiltrating. These cancers have broken through the ductal or glandular walls where they originated and grown into surrounding breast tissue.

The prognosis (forecast or outcome) of invasive breast cancer is strongly influenced by the stage of the disease – that is, the extent or spread of the cancer when it is first diagnosed. There are two main staging systems for cancer. The TNM classification of tumors uses information on tumor size and how far it has spread within the breast (T), the extent of spread to the nearby lymph nodes (N), and the presence or absence of distant metastases (spread to distant organs) (M). Once the T, N, and M are determined, a stage of 0, I, II, III, or IV is assigned, with stage 0 being in situ, stage I being early stage invasive cancer, and stage IV being the most advanced disease. The TNM staging system is commonly used in clinical settings.

The Surveillance, Epidemiology, and End Results (SEER) Summary Stage system is more simplified and is commonly used in reporting cancer registry data and for public health research and planning.

According to this system:
- Local stage refers to cancers that are confined to the breast (corresponding to stage I and some stage II cancers in the TNM staging system).
- Regional stage refers to tumors that have spread to surrounding tissue or nearby lymph nodes (generally corresponding to stage II or III cancers, depending on size and lymph node involvement).
- Distant stage refers to cancers that have metastasized (spread) to distant organs or lymph nodes above the collarbone (corresponding to stages IIIc and IV).

Table 1. Estimated New Female Breast Cancer Cases and Deaths by Age, US, 2013*

<table>
<thead>
<tr>
<th>Age (Yrs)</th>
<th>In Situ Cases</th>
<th>Invasive Cases</th>
<th>Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;40</td>
<td>1,900</td>
<td>10,980</td>
<td>1,020</td>
</tr>
<tr>
<td>&lt;50</td>
<td>15,650</td>
<td>48,910</td>
<td>4,780</td>
</tr>
<tr>
<td>50-64</td>
<td>26,770</td>
<td>84,210</td>
<td>11,970</td>
</tr>
<tr>
<td>65+</td>
<td>22,220</td>
<td>99,220</td>
<td>22,870</td>
</tr>
<tr>
<td>All ages</td>
<td>64,640</td>
<td>232,340</td>
<td>39,620</td>
</tr>
</tbody>
</table>

*Rounded to the nearest 10.
Source: Total estimated cases are based on 1995-2009 incidence rates from 49 states as reported by the North American Association for Central Cancer Registries. Total estimated deaths are based on data from US Mortality Data, 1995-2009, National Center for Health Statistics, Centers for Disease Control and Prevention.

American Cancer Society, Surveillance and Health Services Research, 2013
Breast cancer is increasingly considered to be not one disease, but a group of diseases distinguished by different molecular subtypes, risk factors, clinical behaviors, and responses to treatment. Distinct molecular subtypes of breast cancer have been identified using gene expression profiles, a process that is both complex and costly. More convenient approximations of molecular subtypes have been identified using biological markers, including the presence or absence of estrogen receptors (ER+/ER-), progesterone receptors (PR+/PR-), and human epidermal growth factor receptor 2 (HER2+/HER2-). Molecular subtypes are increasingly being used for research purposes; however, questions remain about their usefulness to further tailor breast cancer treatments and predict breast cancer prognosis.

- **Luminal A.** About 40% of breast cancers are luminal A, making it the most common breast cancer subtype. These tumors tend to be ER+ and/or PR+ and HER2-, slow-growing, and less aggressive than other subtypes. Luminal A tumors are associated with the most favorable short-term prognosis, in part because expression of hormone receptors is predictive of a favorable response to hormonal therapy (see page 25); however, long-term survival is similar to or even lower than some other subtypes.

- **Luminal B.** About 10% to 20% of breast cancers are luminal B. Like luminal A tumors, most luminal B tumors are ER+ and/or PR+, but they are distinguished by either expression of HER2 or high proliferation rates (high numbers of cancer cells actively dividing).

- **Basal-like.** About 10% to 20% of breast cancers are basal-like, and the majority of basal-like breast cancers are referred to as "triple negative" because they are ER-, PR-, and HER2-. Basal-like tumors are more common in African American women, premenopausal women, and those with a BRCA1 gene mutation. Women diagnosed with basal-like breast cancer have a poorer short-term prognosis than those diagnosed with other breast cancer types because there are no targeted therapies for these tumors.

- **HER2 enriched.** About 10% of breast cancers produce excess HER2 (a growth-promoting protein) and do not express hormone receptors (ER- and PR-). Similar to the basal-like subtype, these cancers tend to grow and spread more aggressively than other breast cancers and are associated with poorer short-term prognosis compared to ER+ breast cancers. However, the use of targeted therapies for HER2+ cancers has reversed much of the adverse prognostic impact of HER2 overexpression. For more information about the treatment of HER2+ breast cancers, see the section on targeted therapy on page 25.

**What are the signs and symptoms of breast cancer?**

Breast cancer typically produces no symptoms when the tumor is small and most easily cured. Therefore, it is very important for women to follow recommended screening guidelines for detecting breast cancer at an early stage. When breast cancer has grown to a size that can be felt, the most common physical sign is a painless lump. Sometimes breast cancer can spread to underarm lymph nodes and cause a lump or swelling, even before the original breast tumor is large enough to be felt. Less common signs and symptoms include breast pain or heaviness; persistent changes to the breast, such as swelling, thickening, or redness of the breast’s skin; and nipple abnormalities such as spontaneous discharge (especially if bloody), erosion, inversion, or tenderness. It is important to note that pain (or lack thereof) does not indicate the presence or the absence of breast cancer. Any persistent abnormality in the breast should be evaluated by a physician as soon as possible.
Table 2. Female Breast Cancer Incidence and Mortality Rates* by Race, Ethnicity, and State, 2006-2010

<table>
<thead>
<tr>
<th>State</th>
<th>Non-Hispanic White</th>
<th></th>
<th>African American</th>
<th></th>
<th>Hispanic</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Incidence</td>
<td>Mortality</td>
<td>Incidence</td>
<td>Mortality</td>
<td>Incidence</td>
<td>Mortality</td>
</tr>
<tr>
<td>Alabama</td>
<td>117.9</td>
<td>21.0</td>
<td>121.2</td>
<td>31.5</td>
<td>56.8 †</td>
<td></td>
</tr>
<tr>
<td>Alaska</td>
<td>130.7</td>
<td>25.2</td>
<td>147.5</td>
<td>†</td>
<td>90.3 †</td>
<td></td>
</tr>
<tr>
<td>Arizona</td>
<td>117.1</td>
<td>21.5</td>
<td>95.7</td>
<td>27.7</td>
<td>84.4 16.4</td>
<td></td>
</tr>
<tr>
<td>Arkansas</td>
<td>109.6</td>
<td>22.3</td>
<td>100.8</td>
<td>32.9</td>
<td>50.7 †</td>
<td></td>
</tr>
<tr>
<td>California</td>
<td>140.6</td>
<td>24.7</td>
<td>120.7</td>
<td>31.8</td>
<td>89.9 15.2</td>
<td></td>
</tr>
<tr>
<td>Colorado</td>
<td>127.9</td>
<td>20.2</td>
<td>121.5</td>
<td>23.3</td>
<td>98.3 14.2</td>
<td></td>
</tr>
<tr>
<td>Connecticut</td>
<td>140.2</td>
<td>21.8</td>
<td>110.9</td>
<td>27.0</td>
<td>119.6 11.9</td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td>126.9</td>
<td>23.3</td>
<td>126.7</td>
<td>23.4</td>
<td>112.8 †</td>
<td></td>
</tr>
<tr>
<td>Dist. of Columbia†</td>
<td>160.5</td>
<td>22.6</td>
<td>133.6</td>
<td>34.7</td>
<td>71.8</td>
<td></td>
</tr>
<tr>
<td>Florida</td>
<td>119.7</td>
<td>21.5</td>
<td>105.4</td>
<td>29.1</td>
<td>96.5 15.0</td>
<td></td>
</tr>
<tr>
<td>Georgia</td>
<td>124.0</td>
<td>21.9</td>
<td>120.9</td>
<td>29.6</td>
<td>85.8 6.0</td>
<td></td>
</tr>
<tr>
<td>Hawaii</td>
<td>130.4</td>
<td>19.9</td>
<td>128.5</td>
<td>†</td>
<td>112.9 18.4</td>
<td></td>
</tr>
<tr>
<td>Idaho</td>
<td>121.6</td>
<td>22.3</td>
<td>†</td>
<td>†</td>
<td>80.2 †</td>
<td></td>
</tr>
<tr>
<td>Illinois</td>
<td>131.6</td>
<td>23.2</td>
<td>123.4</td>
<td>33.4</td>
<td>87.2 10.8</td>
<td></td>
</tr>
<tr>
<td>Indiana</td>
<td>118.1</td>
<td>23.6</td>
<td>117.6</td>
<td>31.6</td>
<td>70.9 8.8</td>
<td></td>
</tr>
<tr>
<td>Iowa</td>
<td>124.6</td>
<td>21.6</td>
<td>114.0</td>
<td>28.3</td>
<td>68.8 †</td>
<td></td>
</tr>
<tr>
<td>Kansas</td>
<td>123.1</td>
<td>22.3</td>
<td>124.0</td>
<td>28.1</td>
<td>88.7 11.2</td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td>121.5</td>
<td>22.7</td>
<td>129.4</td>
<td>32.9</td>
<td>60.5 †</td>
<td></td>
</tr>
<tr>
<td>Louisiana</td>
<td>119.9</td>
<td>22.7</td>
<td>124.6</td>
<td>33.8</td>
<td>80.0 9.6</td>
<td></td>
</tr>
<tr>
<td>Maine</td>
<td>127.3</td>
<td>20.8</td>
<td>†</td>
<td>†</td>
<td>† † †</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td>131.3</td>
<td>22.8</td>
<td>125.7</td>
<td>31.7</td>
<td>82.6 10.5</td>
<td></td>
</tr>
<tr>
<td>Massachusetts§</td>
<td>137.9</td>
<td>21.8</td>
<td>97.7</td>
<td>23.2</td>
<td>– 10.0</td>
<td></td>
</tr>
<tr>
<td>Michigan</td>
<td>118.7</td>
<td>22.8</td>
<td>119.4</td>
<td>34.3</td>
<td>80.1 15.8</td>
<td></td>
</tr>
<tr>
<td>Minnesota†</td>
<td>–</td>
<td>21.1</td>
<td>–</td>
<td>21.9</td>
<td>– † †</td>
<td></td>
</tr>
<tr>
<td>Mississippi</td>
<td>112.3</td>
<td>20.8</td>
<td>117.3</td>
<td>33.4</td>
<td>35.1</td>
<td></td>
</tr>
<tr>
<td>Missouri</td>
<td>121.5</td>
<td>23.7</td>
<td>130.9</td>
<td>32.4</td>
<td>70.5 †</td>
<td></td>
</tr>
<tr>
<td>Montana</td>
<td>123.5</td>
<td>20.0</td>
<td>†</td>
<td>†</td>
<td>113.5 †</td>
<td></td>
</tr>
<tr>
<td>Nebraska</td>
<td>123.7</td>
<td>22.0</td>
<td>122.8</td>
<td>27.5</td>
<td>97.9 19.3</td>
<td></td>
</tr>
<tr>
<td>Nevada</td>
<td>120.6</td>
<td>24.9</td>
<td>103.7</td>
<td>26.6</td>
<td>79.9 9.9</td>
<td></td>
</tr>
<tr>
<td>New Hampshire</td>
<td>133.1</td>
<td>21.5</td>
<td>107.3</td>
<td>†</td>
<td>90.9 †</td>
<td></td>
</tr>
<tr>
<td>New Jersey</td>
<td>139.4</td>
<td>26.2</td>
<td>117.1</td>
<td>30.9</td>
<td>91.8 13.2</td>
<td></td>
</tr>
<tr>
<td>New Mexico</td>
<td>122.9</td>
<td>22.4</td>
<td>83.4</td>
<td>†</td>
<td>93.3 19.3</td>
<td></td>
</tr>
<tr>
<td>New York</td>
<td>138.4</td>
<td>22.9</td>
<td>109.0</td>
<td>25.8</td>
<td>99.8 15.6</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td>127.2</td>
<td>21.9</td>
<td>123.0</td>
<td>29.9</td>
<td>79.4 6.7</td>
<td></td>
</tr>
<tr>
<td>North Dakota‡</td>
<td>122.9</td>
<td>21.1</td>
<td>†</td>
<td>†</td>
<td>† † †</td>
<td></td>
</tr>
<tr>
<td>Ohio</td>
<td>119.2</td>
<td>24.2</td>
<td>116.2</td>
<td>31.6</td>
<td>64.0 9.3</td>
<td></td>
</tr>
<tr>
<td>Oklahoma</td>
<td>120.0</td>
<td>24.0</td>
<td>129.4</td>
<td>34.7</td>
<td>106.4 11.4</td>
<td></td>
</tr>
<tr>
<td>Oregon</td>
<td>130.2</td>
<td>22.3</td>
<td>106.7</td>
<td>22.0</td>
<td>100.4 12.6</td>
<td></td>
</tr>
<tr>
<td>Pennsylvania</td>
<td>126.5</td>
<td>23.4</td>
<td>127.8</td>
<td>32.1</td>
<td>90.9 12.6</td>
<td></td>
</tr>
<tr>
<td>Rhode Island</td>
<td>137.3</td>
<td>21.5</td>
<td>104.0</td>
<td>19.7</td>
<td>67.2 †</td>
<td></td>
</tr>
<tr>
<td>South Carolina‡</td>
<td>124.0</td>
<td>21.3</td>
<td>118.5</td>
<td>29.8</td>
<td>74.6 †</td>
<td></td>
</tr>
<tr>
<td>South Dakota†</td>
<td>119.0</td>
<td>20.7</td>
<td>†</td>
<td>†</td>
<td>† † †</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td>118.9</td>
<td>21.8</td>
<td>122.7</td>
<td>35.4</td>
<td>57.1 †</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td>124.6</td>
<td>22.0</td>
<td>117.2</td>
<td>33.5</td>
<td>89.4 16.7</td>
<td></td>
</tr>
<tr>
<td>Utah</td>
<td>113.7</td>
<td>22.8</td>
<td>96.7</td>
<td>†</td>
<td>83.4 13.6</td>
<td></td>
</tr>
<tr>
<td>Vermont</td>
<td>133.2</td>
<td>20.7</td>
<td>†</td>
<td>†</td>
<td>† † †</td>
<td></td>
</tr>
<tr>
<td>Virginia</td>
<td>126.8</td>
<td>22.8</td>
<td>127.3</td>
<td>33.2</td>
<td>87.3 12.2</td>
<td></td>
</tr>
<tr>
<td>Washington</td>
<td>134.8</td>
<td>22.7</td>
<td>116.4</td>
<td>24.5</td>
<td>83.4 9.4</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td>110.7</td>
<td>22.2</td>
<td>105.7</td>
<td>25.8</td>
<td>† † †</td>
<td></td>
</tr>
<tr>
<td>Wisconsin</td>
<td>123.4</td>
<td>21.3</td>
<td>116.5</td>
<td>29.1</td>
<td>85.2 9.8</td>
<td></td>
</tr>
<tr>
<td>Wyoming</td>
<td>113.2</td>
<td>21.4</td>
<td>†</td>
<td>†</td>
<td>91.0 †</td>
<td></td>
</tr>
<tr>
<td>United States††</td>
<td>127.3</td>
<td>22.7</td>
<td>118.4</td>
<td>30.8</td>
<td>91.1 14.8</td>
<td></td>
</tr>
</tbody>
</table>

*Rates are per 100,000 and age adjusted to 2000 US standard population. † Statistic not displayed due to fewer than 25 cases or deaths. †† Mortality rates for white women in these states are not exclusive of Hispanic origin and are not shown for Hispanic women due to unreliable ethnicity data. §The incidence rate for white women in Massachusetts is not exclusive of Hispanic origin and is not available for Hispanic women. ¶This state’s registry did not submit 2006-2010 incidence data to the North American Association of Central Cancer Registries. †† Overall US incidence rates do not include data from Arkansas, Minnesota, Nevada, Ohio, and Virginia.

Sources: Incidence: Copeland et al.† mortality: National Center for Health Statistics, Centers for Disease Control and Prevention, as provided by the Surveillance, Epidemiology, and End Results Program, National Cancer Institute.

American Cancer Society, Surveillance and Health Services Research, 2013
Breast Cancer Occurrence

How many cases and deaths are estimated to occur in 2013?

- In 2013, an estimated 232,340 new cases of invasive breast cancer will be diagnosed among women, as well as an estimated 64,640 additional cases of in situ breast cancer (Table 1, page 1).
- In 2013, approximately 39,620 women are expected to die from breast cancer (Table 1, page 1). Only lung cancer accounts for more cancer deaths in women.
- In 2013, about 2,240 men will be diagnosed with breast cancer and 410 men will die from the disease.

How many women alive today have ever had breast cancer?

More than 2.9 million US women with a history of breast cancer were alive on January 1, 2012. Some of these women were cancer-free, while others still had evidence of cancer and may have been undergoing treatment.

Who gets breast cancer?

Sex

- Excluding cancers of the skin, breast cancer is the most common cancer among US women, accounting for 29% of newly diagnosed cancers.
- Men are generally at low risk for developing breast cancer; however, they should report any change in their breasts to a physician.

Age

- Breast cancer incidence and death rates generally increase with age (Figure 1, page 2). Seventy-nine percent of new cases and 88% of breast cancer deaths occurred in women 50 years of age and older.
- The decrease in incidence rates that occurs in women 80 years of age and older may reflect lower rates of screening, the detection of cancers by mammography before 80 years of age, and/or incomplete detection.
- During 2006-2010, the median age at the time of breast cancer diagnosis was 61. This means that half of women who developed breast cancer were 61 years of age or younger at the time of diagnosis.
- A woman living in the US has a 12.3%, or a 1 in 8, lifetime risk of being diagnosed with breast cancer. In the 1970s, the lifetime risk of being diagnosed with breast cancer was 1 in 11. This increase in risk is due to longer life expectancy, as well as increases in breast cancer incidence due in part to changes in reproductive patterns, menopausal hormone use, the rising prevalence of obesity, and increased detection through screening. Lifetime risk reflects an average woman’s risk over an entire lifetime, including the possibility that she may die from another cause before she would have been diagnosed with breast cancer, and should not be confused with risk over a shorter time period.

Race/Ethnicity

- Breast cancer incidence rates are higher in non-Hispanic white women than African American women for most age groups (Figure 1, page 2). However, African American women have a higher incidence rate before age 40 and are more likely to die from breast cancer at every age. In addition, African American women have lower rates of ER+ breast cancer and higher rates of ER- breast cancer than white women in every age group.
- Figure 2 shows breast cancer incidence and death rates by race and ethnicity during the most recent time period (2006-2010). Incidence and death rates for breast cancer are lower among women of other racial and ethnic groups than among non-Hispanic white and African American women. Asian/Pacific Islander women have the lowest incidence and death rates.
Figure 3. Female Breast Cancer Death Rates* by Race and Ethnicity, US, 2006-2010

*Per 100,000 and age adjusted to the 2000 US standard population.
Note: Statistic not displayed for states with fewer than 25 deaths. Death rates for whites in DC, ND, and SC are not exclusive of Hispanic origin due to unreliable ethnicity data.

Source: National Center for Health Statistics, Centers for Disease Control and Prevention, as provided by the Surveillance, Epidemiology, and End Results Program, National Cancer Institute.

American Cancer Society, Surveillance and Health Services Research, 2013
**Are there geographic differences in breast cancer rates?**

Table 2 (page 3) shows breast cancer incidence and death rates per 100,000 women for non-Hispanic white, African American, and Hispanic women by state. Breast cancer incidence rates range from 109.6 (cases per 100,000 women) in Arkansas to 160.5 in the District of Columbia among non-Hispanic white women; 83.4 in New Mexico to 147.5 in Alaska among African American women; and 35.1 in Mississippi to 119.6 in Connecticut among Hispanic women. Incidence rates reflect disease occurrence, as well as how completely the population is screened.

Despite higher incidence rates, breast cancer death rates are generally lower among non-Hispanic white women compared to African American women. Death rates reflect both cancer incidence rates and survival. Breast cancer death rates range from 19.9 in Hawaii to 26.2 in New Jersey among non-Hispanic white women and from 19.7 in Rhode Island to 35.4 in Tennessee among African American women. Breast cancer death rates are lowest for Hispanic women and range from 6.0 in Georgia to 19.3 in Nebraska.

Breast cancer mortality rates among non-Hispanic white women tend to be highest in the West, Midwest, and Mid-Atlantic regions of the US. Among African American women, the highest death rates are found in some of the Southern and Midwestern states (Figure 3, page 5).

**How has the occurrence of breast cancer changed over time?**

**Incidence trends – women**

Figure 4 presents trends for in situ and invasive breast cancer incidence rates since 1975, when population-based cancer registration began in the nine oldest cancer registries.

**In situ breast cancer**

Incidence rates of in situ breast cancer rose rapidly during the 1980s and 1990s (Figure 4a), largely because of increases in mammography screening. The increase in incidence was greater in women 50 years of age and older than in those younger than 50. Since 1999, incidence rates of in situ breast cancer have stabilized among women 50 and older, but continue to increase in younger women (1.9% per year from 1998 to 2010). The stabilization in incidence among women 50 years of age and older likely reflects trends in mammography screening rates, which peaked in 2000 and then stabilized at a slightly lower rate. It may also reflect a reduced pool of prevalent cases as a result of widespread screening.

**Invasive breast cancer**

Much of the historic increase in breast cancer incidence reflects changes in reproductive patterns, such as delayed childbearing and having fewer children, which are recognized risk factors for breast cancer. However, between 1980 and 1987, breast cancer incidence rates increased rapidly, due largely to greater use of
mammography screening, which can detect breast cancers too small to be felt. The widespread uptake of mammography screening inflated the incidence rate because cancers were being diagnosed 1 to 3 years earlier than they would have in the absence of screening. Rates stabilized in the early 1990s, followed by a slower increase during the latter half of the decade. This trend may reflect further increases in the prevalence of mammography screening, as well as rising rates of obesity and the use of menopausal hormones, both of which increase breast cancer risk. Between 2002 and 2003, breast cancer rates dropped sharply (nearly 7%), likely due to the decreased use of menopausal hormones following the 2002 publication of the Women’s Health Initiative randomized trial results.\textsuperscript{17,18} The decline occurred primarily in white women, in women ages 50 and older, and for ER+ disease.\textsuperscript{17,19} This trend may also reflect declines in mammography screening. The percentage of women 40 years of age and older who reported having a mammogram within the past 2 years peaked in 2000, declined slightly, and has since stabilized.\textsuperscript{16} Similar reversals in breast cancer trends have been observed internationally, as well.\textsuperscript{20-24} Since 2004, overall breast cancer incidence rates have remained relatively stable.\textsuperscript{14}

**Race/Ethnicity:** Figure 5a presents trends in invasive female breast cancer incidence rates by race and ethnicity. Incidence data are available for white and African American women since 1975 and for women of other races and ethnicities since 1992. During 2006-2010 (the most recent 5 years of data available), overall breast cancer incidence rates increased slightly (0.2% per year) among African American women, decreased by 0.6% per year in Hispanic women, and did not change significantly among whites, Asians/Pacific Islanders (API), or American Indians/Alaska Natives (AI/AN).\textsuperscript{14} Notably, rates for white and African American women are converging. Please note that rates for white and African American women were adjusted for delays in case reporting; delay-adjusted rates are not available for other races/ethnicities, resulting in slightly underestimated rates, particularly for the most recent data years. Also, rates for American Indians/Alaska Natives are based on limited geographic areas with high-quality data.

**Age:** Trends for invasive breast cancer by age at diagnosis are shown in Figure 4b. Overall breast cancer incidence rates have been relatively stable for both women under the age of 50 and those ages 50 and older during the most recent time period (2006-2010). However, trends by age at diagnosis vary by race and ethnicity. Although the overall incidence trends for white and API women were stable, rates increased slightly during 2006-2010 for white and API women younger than 50 by 0.1% and 0.8% per year, respectively.\textsuperscript{14} Among women 50 years of age and older, incidence rates decreased slightly in Hispanics (0.7% per year) and increased slightly (0.3% per year) in African Americans.\textsuperscript{14} Incidence rates were stable for white, Asian/Pacific Islander, and American Indian/Alaska Native women 50 years of age and older during 2006-2010.\textsuperscript{14}
**Tumor size:** Incidence rates of breast cancer by tumor size differ between white and African American women. African American women are less likely to be diagnosed with smaller tumors (≤2.0 cm) and more likely to be diagnosed with larger tumors (> 5.0 cm) than white women.

Figure 6a describes trends in incidence rates by tumor size and race. For smaller tumors (≤ 2.0 cm), incidence rates decreased by 1.1% per year during 2006-2010 among white women, but were stable among African American women. The incidence rate for tumors 2.1-5.0 cm increased during 2006-2010 for both white and African American women, by 1.1% and 0.5% per year, respec-
tively. For the largest tumors (>5.0 cm), incidence rates were relatively stable among white women during the most recent time period, but increased slightly by 0.7% per year on average for African American women.

**Stage:** Figure 6b presents incidence trends by race and stage at diagnosis. Among both African American and white women, incidence rates of localized breast cancer increased through most of the 1980s and 1990s, but have been relatively stable during the most recent time period (2006-2010). Among white women, incidence rates of regional-stage disease decreased on average 1.6% per year during 2006-2010, whereas the rate of distant-stage tumors increased over this period (1.8% per year). This shift toward later stage at diagnosis may reflect improvements in tumor staging. Rates of distant-stage breast cancer also increased among African American women by 1.4% per year from 2006-2010.

**Mortality trends – women**

After slowly increasing for many years (0.4% per year from 1975-1990), breast cancer death rates decreased by 34% from 1990 to 2010. The decline has been faster among women younger than 50 (3.1% per year) than women 50 and older (1.9% per year). From 2001 through 2010, breast cancer death rates declined annually by 1.8% in non-Hispanic whites, 1.7% in Hispanics/Latinas, 1.6% in African Americans, and 1.0% in Asians/Pacific Islanders, but remained unchanged among American Indians/Alaska Natives.

The drop in breast cancer mortality has been attributed to both improvements in breast cancer treatment and early detection. However, not all segments of the population have benefited equally from these advances. A striking divergence in long-term breast cancer mortality trends between African American and white women began in the early 1980s (Figure 5b, page 7). This mortality difference may reflect earlier uptake and greater mammography usage by whites during the 1980s, as well as differences in access and response to new treatments, including tamoxifen, which is used to treat hormone receptor-positive breast cancers, which are less common among African American women. By 2010, breast cancer death rates were 41% higher in African American than white women.

Trends in breast cancer death rates also vary by state. During 2001-2010, breast cancer death rates among all women combined significantly decreased in 36 states, but remained relatively unchanged in the remaining 14 states (Alaska, Arkansas, Delaware, Hawaii, Idaho, Maine, Montana, Nebraska, Nevada, New Mexico, South Dakota, Utah, West Virginia, and Wyoming) and the District of Columbia. The lack of a decline in these states is likely related to variations in the prevalence and quality of mammography screening, as well as state differences in racial and socioeconomic composition.

**Incidence and mortality trends – men**

Figure 7 presents incidence and mortality trends for male breast cancer. Breast cancer in men is rare, accounting for approximately 1% of breast cancer cases in the US. However, since 1975, the incidence rate increased 0.8% annually, from 1.0 case per 100,000 men during 1975-1979 to 1.2 cases per 100,000 men during 2005-2010. The increase has been limited to in situ and local-stage tumors, which may reflect a shift to earlier diagnoses due to increased awareness and follow up of breast symptoms.

Mammography is not recommended for men because of the rarity of the disease. Similar to female breast cancer, the incidence of male breast cancer increases with age; however, unlike female breast cancer, incidence rates are higher in African American men than white men. Death rates for male breast cancer have decreased 1.8% per year since 2000.

Due to the infrequency of male breast cancer, much less is known about the disease than female breast cancer. Risk factors include radiation exposure, **BRCA** gene mutations, Klinefelter syndrome, testicular disorders, family history of male or female breast cancer, and obesity.

**Breast cancer survival and stage at diagnosis**

Relative survival rates are an estimate of the percentage of patients who will survive for a given period of time after a cancer diagnosis. It differs from observed survival in that it accounts for deaths from other causes by comparing survival among cancer patients to the survival among the general population of the same age, sex, and calendar year. The survival benefit from mammography screening is greater in women younger than 50 years old, particularly for African American women.
patients to survival among people of the same age and race who have not been diagnosed with cancer.

Based on the most recent data, relative survival rates for women diagnosed with breast cancer are:
- 89% at 5 years after diagnosis
- 83% after 10 years
- 78% after 15 years

Relative survival rates should be interpreted with caution. First, they do not predict individual prognosis because many patient and tumor characteristics that influence breast cancer survival are not taken into account. Second, long-term survival rates are based on the experience of women treated many years ago and do not reflect the most recent improvements in early detection or treatment.

Stage at diagnosis

Five-year relative survival is lower among women with a more advanced stage at diagnosis (Figure 8a). Considering all races, 5-year relative survival is 99% for localized disease, 84% for regional disease, and 24% for distant-stage disease.14 Larger tumor size at diagnosis is also associated with decreased survival. For example, among women with regional disease, the 5-year relative survival is 95% for tumors less than or equal to 2.0 cm, 83% for tumors 2.1-5.0 cm, and 65% for tumors greater than 5.0 cm.

Age at diagnosis

The 5-year relative survival rate is lower among women diagnosed with breast cancer before age 40 (85%) compared to women diagnosed at 40 years of age or older (90%). This may be due to tumors diagnosed at younger ages being more aggressive and/or less responsive to treatment.31,32

Race/ethnicity and socioeconomic factors

Since 1975, the breast cancer 5-year relative survival rate has increased significantly for both African American and white women; nevertheless, there remains a substantial racial gap (Figure 9). In the most recent period, the 5-year relative survival rate was 79% for African American women and 92% among white women.14 This survival disparity is attributed to both later stage at detection and poorer stage-specific survival among African American women (Figure 8).

Table 3 presents 5-year cause-specific breast cancer survival rates by race and ethnicity. Cause-specific survival instead of relative survival is used to describe the cancer experience of racial and ethnic minorities because estimates of normal life expectancy are not available for most racial groups. Cause-specific survival is the probability of not dying of breast cancer within 5 years of diagnosis. African American women have the lowest survival rate of any racial or ethnic group.

Poverty, less education, and a lack of health insurance are also associated with lower breast cancer survival.33,34 Breast cancer patients who reside in lower-income areas have lower 5-year survival rates than those in higher-income areas at every stage of diagnosis.35 The presence of additional illnesses, unequal access to medical care, and disparities in receipt of treatment likely contribute to differences in breast cancer survival.36-41 Aggressive tumor characteristics associated with poorer prognosis appear to be more common in African American women and may also contribute to lower survival rates.12,42

Figure 8. Female Breast Cancer Survival and Stage Distribution, 2003-2009*

<table>
<thead>
<tr>
<th>Stage</th>
<th>African American</th>
<th>All Races</th>
<th>White</th>
</tr>
</thead>
<tbody>
<tr>
<td>Localized</td>
<td>54</td>
<td>94</td>
<td>99</td>
</tr>
<tr>
<td>Regional</td>
<td>74</td>
<td>86</td>
<td>84</td>
</tr>
<tr>
<td>Distant</td>
<td>16</td>
<td>25</td>
<td>24</td>
</tr>
<tr>
<td>Unstaged</td>
<td>48</td>
<td>48</td>
<td>50</td>
</tr>
</tbody>
</table>

*Survival rates are based on patients diagnosed between 2003 and 2009 and followed through 2010.

Source: Howlader et al.14

American Cancer Society, Surveillance and Health Services Research, 2013
Breast Cancer Risk Factors

Many of the known breast cancer risk factors listed in Table 4 (page 12), such as sex, age, family history, early menarche, and late menopause, are not modifiable, that is they cannot be changed. However, other factors associated with increased breast cancer risk, including postmenopausal obesity, use of combined estrogen and progestin menopausal hormones, cigarette smoking, and alcohol consumption are modifiable. Many risk factors affect lifetime exposure of breast tissue to hormones (early menarche, late menopause, obesity, and hormone use). Reproductive hormones are thought to influence breast cancer risk by increasing cell proliferation, thereby increasing the likelihood of DNA damage, as well as promotion of cancer growth. Many of the known risk factors for breast cancer are specifically associated with the ER+/luminal A subtype; less is known about risk factors for ER- and triple negative (basal-like) breast cancers.

Strategies that may help reduce the risk of breast cancer include avoiding weight gain and obesity, engaging in regular physical activity, and minimizing alcohol intake (see American Cancer Society guidelines, page 15). Women who choose to breastfeed for an extended period of time (studies suggest a year or more) may also reduce their breast cancer risk. Women should consider the increased risk of breast cancer associated with the use of estrogen and progestin when evaluating treatment options for menopausal symptoms. Treatment with tamoxifen or raloxifene can also reduce the risk of breast cancer among women at high risk (see page 17 for section on chemoprevention). Breast cancer risk factors, along with factors that may decrease the risk of breast cancer, are discussed below.

Personal and family history

Family history of breast cancer

Women (as well as men) with a family history of breast cancer, especially in a first-degree relative (mother, sister, daughter, father, or brother), are at increased risk of developing breast cancer; this risk is higher if more than one first-degree relative developed breast cancer. Compared to women without a family history, risk of breast cancer is 1.8 times higher for women with one first-degree female relative who has been diagnosed, nearly 3 times higher for women with two relatives, and nearly 4 times higher for women with three or more relatives. Risk is further increased when the affected relative was diagnosed at a young age.

It is important to note that the majority of women with one or more affected first-degree relatives will never develop breast cancer and that most women who develop breast cancer do not have a family history of the disease. A family history of ovarian cancer is also associated with increased breast cancer risk in both men and women. Women with a history of breast or ovarian cancer...
cancer in their immediate family or in either parent’s extended family should discuss this with their physicians because it may signal the presence of a genetic predisposition to cancer.

Genetic predisposition

It is estimated that 5% to 10% of breast cancer cases result from inherited mutations, including those in the breast cancer susceptibility genes BRCA1 and BRCA2. These mutations are present in less than 1% of the general population, but occur more often in certain ethnic groups such as those of Ashkenazi (Eastern European) Jewish descent. The estimates of the risk of breast cancer in women with these mutations vary; by age 70, between 44% and 78% of women with BRCA1 mutations and between 31% and 56% of women with BRCA2 mutations will develop breast cancer.

Only about 15%-20% of familial breast cancers are attributed to BRCA1 or BRCA2 gene mutations. Other inherited conditions associated with smaller increased breast cancer risk include Li-Fraumeni and Cowden syndromes and a number of more common genetic mutations. These mutations can be inherited from either parent and by sons as well as daughters.

In addition, low-risk variations in the genetic code may affect breast cancer risk. Scientists believe that much of the occurrence of breast cancer in families results from the interaction between lifestyle factors and these low-risk variations that may be shared within a family.

Molecular tests are commercially available to identify some of the BRCA mutations, as well as many of the family cancer syndromes responsible for inherited forms of breast cancer; however, the interpretation of these tests and treatment decisions remains complicated. It is not yet possible to predict if or when women who carry a particular genetic abnormality will develop breast cancer. Furthermore, tests are not available for all of the genes that affect breast cancer risk.

The US Preventive Services Task Force (USPTF) currently recommends that only women with a strong family history (about 2% of US women) be evaluated for genetic testing for BRCA mutations (see recommendations, opposite page). The American Cancer Society, the American Society for Clinical Oncology, and other organizations strongly recommend that any person who is considering genetic testing talk with a genetic counselor before making a decision about testing so that the benefits and potential consequences can be understood and carefully considered. For more information, see the American Cancer Society document called Genetic Testing: What You Need to Know, which is available at cancer.org.

Personal history of breast cancer

Women with a history of breast cancer are at increased risk for developing a second breast cancer. The risk is higher if the diagnosis was at a younger age. Women diagnosed with early onset breast cancer (age <40) have almost a 4.5-fold increased risk of subsequent breast cancer. Genetic predisposition, such as mutations in BRCA1 and BRCA2 genes, probably contribute to some of the excess risk of subsequent breast cancers, particularly among women diagnosed at a young age.

Lobular carcinoma in situ

This uncommon condition is the result of abnormal cells forming in the lobules or milk-producing glands of the breast. Although LCIS seldom becomes invasive cancer, women with LCIS are 7 to 12 times more likely to develop invasive cancer in either breast than women without LCIS. LCIS is not usually apparent on a mammogram and is typically discovered during a biopsy performed for another reason, such as an abnormal mammogram. Pure LCIS should be distinguished from DCIS and pleomorphic LCIS, as both of these conditions are considered precursor lesions for breast cancer and require cancer-directed therapy.

<table>
<thead>
<tr>
<th>Table 4. Factors That Increase the Relative Risk for Breast Cancer in Women</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relative Risk</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>&gt;4.0</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>2.1-4.0</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>1.1-2.0</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
Benign breast disease

Some types of benign breast conditions are linked to breast cancer risk. Doctors often categorize these conditions into 3 general groups, reflecting the degree of risk: nonproliferative lesions, proliferative lesions without atypia (abnormal cells or patterns of cells), and proliferative lesions with atypia. Nonproliferative lesions are not associated with overgrowth of breast tissue and have little to no effect on breast cancer risk. Examples of nonproliferative lesions include fibrosis (also known as fibrocystic changes), simple cysts, and mild hyperplasia. Proliferative lesions without atypia are associated with a small increase in the risk of breast cancer (1.5 to 2 times the risk of those who do not have one of these lesions) and include non-atypical (or usual) ductal hyperplasia and fibroadenoma.\textsuperscript{55-58} Proliferative lesions with atypia are associated with the greatest breast cancer risk – 4 to 5 times higher than average risk.\textsuperscript{55,56,58} These include atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH). Women should keep detailed records of any benign breast biopsy results, as this information is valuable for risk assessment, screening, and counseling for chemoprevention and risk-reduction strategies.

Breast density

High breast tissue density (a mammographic indicator of the amount of breast and connective tissue relative to fatty tissue in the breast) has been shown to be a strong, independent risk factor for the development of breast cancer.\textsuperscript{59} A number of factors can affect breast density, such as age, menopausal status, the use of certain drugs (such as menopausal hormone therapy), pregnancy, and genetics. Breast density is influenced by inherited genetic factors, but decreases with age and is further reduced by pregnancy and menopause.\textsuperscript{60,61} Percent breast density is generally lower among women with higher body weight because of the higher proportion of fatty tissue.\textsuperscript{62} Some drugs affect breast density, including tamoxifen (decreases density) and combined menopausal hormone therapy (increases density).\textsuperscript{63} The risk of breast cancer increases with increasing breast density; women with very high breast density have a 4- to 6-fold increased risk of breast cancer compared to women with the least dense breasts.\textsuperscript{59,64,65} In addition, mammographic detection of breast cancer is impaired for dense breast tissue.\textsuperscript{64} Some states have laws requiring that women be informed if they have higher than average breast tissue density, along with the other findings on their mammogram. In addition, some states also require that women with dense breasts be told that they may benefit from additional screening.\textsuperscript{66} However, at this time there is no expert consensus about what other tests, if any, should be done in addition to mammograms to screen for breast cancer in women with dense breasts.

Endogenous hormone levels

Postmenopausal women with high levels of endogenous hormones (estrogen or testosterone produced naturally in the body) have about twice the risk of developing breast cancer compared to women with the lowest levels.\textsuperscript{67-69} High circulating hormone levels are associated with and may reflect the effects of other breast cancer risk factors, such as postmenopausal obesity and alcohol use.\textsuperscript{70} The relationship in premenopausal women is less clear, which likely reflects the complexity of measuring hormone levels that vary during the menstrual cycle. Nevertheless, there is growing evidence linking high levels of testosterone to breast cancer risk in premenopausal women.\textsuperscript{71,73} A recent study reported that premenopausal women in the highest quintiles of total and free testosterone had an 80% greater breast cancer risk compared to women in the lowest quintiles.\textsuperscript{71} Two recent reviews concluded that high estrogen levels are also associated with a slight increase in breast cancer risk in premenopausal women.\textsuperscript{56,74}

US Preventive Services Task Force recommendations for genetic testing for BRCA mutations\textsuperscript{51}

Women who are not of Ashkenazi (Eastern European) Jewish heritage should be referred for genetic evaluation if they have any of the following:

- Two first-degree female relatives (mother, sisters, daughters) with breast cancer, one of whom was diagnosed when they were younger than age 50
- Three or more first- or second-degree female relatives (includes grandmothers and aunts) diagnosed with breast cancer
- Both breast and ovarian cancer among first- and second-degree relatives
- A first-degree relative diagnosed with cancer in both breasts
- Two or more first- or second-degree relatives diagnosed with ovarian cancer
- A male relative with breast cancer

Women of Ashkenazi (Eastern European) Jewish heritage should be referred for genetic evaluation if they have:

- A first-degree relative with breast or ovarian cancer
- Two second-degree relatives on the same side of the family with breast or ovarian cancer
Menstrual cycles
Women who have had more menstrual cycles because they started menstruating early (before age 12) and/or went through menopause later (after age 55) have a slightly higher risk of breast cancer. The increased risk may be due to longer lifetime exposure to reproductive hormones.

Pregnancy
Younger age at first full-term pregnancy (<30 years) and a greater number of pregnancies decrease the risk of breast cancer over the long term; however, there appears to be a transient increase in breast cancer risk following a full-term pregnancy, particularly among women who are older at first birth. Pregnancy-related risk factors seem to be more strongly related to hormone receptor-positive than hormone receptor-negative breast cancers.

Breastfeeding
Most studies suggest that breastfeeding for a year or more slightly reduces a woman’s overall risk of breast cancer. The protective effect may be greater for basal-like breast cancers. Longer duration is associated with greater risk reduction. In a review of 47 studies in 30 countries, the risk of breast cancer was reduced by 4.3% for every 12 months of breastfeeding. One possible explanation for this effect may be that breastfeeding inhibits menstruation, thus reducing the lifetime number of menstrual cycles. Another possible explanation relates to structural changes that occur in the breast following lactation and weaning.

Bone mineral density
High bone mineral density in postmenopausal women has been associated with increased risk for breast cancer in many, but not all, studies; risk appears to be most strongly related to ER+ disease. Bone density is not an independent risk factor for breast cancer, but a marker for cumulative estrogen exposure. Bone density is routinely measured to identify women at increased risk for osteoporosis (high bone density indicates absence of osteoporosis) and may help determine a woman’s risk for developing breast cancer.

Lifestyle-related factors
Postmenopausal hormone use
Recent use of menopausal hormones (also referred to as hormone therapy or HT) with combined estrogen and progestin increases the risk of developing and dying from breast cancer, with higher risk associated with longer use. Risk is also greater for women who start hormone therapy soon after the onset of menopause compared to those who begin use later. The increased risk appears to diminish within 5 years of discontinuation of hormone use.

Estrogen alone can be prescribed for women without a uterus, and it is less clear if this therapy increases risk of breast cancer.

Obesity and weight gain
Obesity increases the risk of postmenopausal breast cancer. The risk of postmenopausal breast cancer is about 1.5 times higher in overweight women and about 2 times higher in obese women than normal weight women.
Breast cancer risk associated with excess weight is likely due to high estrogen levels because fat tissue is the largest source of estrogen in postmenopausal women.

Obesity is also a risk factor for type II diabetes, which some studies have linked to modestly increased risk for postmenopausal breast cancer. The inconsistencies likely reflect the complex relationship between obesity and diabetes, as well as the fact that diabetic treatments may further affect risk.

In contrast, some studies have found that obesity protects against developing breast cancer before menopause. A large meta-analysis found that among women ages 40–49, the risk for developing breast cancer was about 14% lower in overweight women and about 26% lower in obese women compared to women who are normal weight. The underlying mechanisms for this inverse relationship are not well understood, but the protective effect may be limited to ER+ breast cancers.

Many studies have looked at whether the timing of weight gain influences breast cancer risk. Results from a study of more than 80,000 registered nurses found that women who gained 55 pounds or more after age 18 had almost 50% greater risk of breast cancer; a gain of 22 pounds or more after menopause was associated with an increased risk of 18%. Although some studies have found weight loss to be associated with reduced risk, results are not consistent. It is more difficult to examine the effect of weight loss on breast cancer because weight loss is often not sustained.

Physical activity
Growing evidence suggests that women who get regular physical activity have a 10%-20% lower risk of breast cancer compared to women who are inactive, with stronger evidence for postmenopausal than premenopausal women. A recent report from the Nurses’ Health Study of more than 95,000 women found that increases in physical activity after menopause lowered breast cancer risk by 10%. The benefit may be due to the effects of physical activity on body mass, hormones, and energy balance.

Diet
Although numerous studies have examined the relationship between food consumption (including fat, soy, dairy, meat, and fruits and vegetables) and breast cancer, there is no conclusive evidence that diet influences breast cancer risk. A recent meta-analysis of animal fat intake and breast cancer, which included more than 20,000 breast cancer cases, concluded there was no association. Similarly, reducing dietary fat in postmenopausal women did not affect risk of breast cancer in the Women’s Health Initiative dietary intervention. However, the timing of the exposure may be important, as findings from the Nurses’ Health Study showed that a high-fat diet during adolescence was associated with a moderate increase in premenopausal breast cancer risk.

It has been suggested that soy consumption may reduce breast cancer risk, in part because of historically low breast cancer rates among Asian women. A meta-analysis showed that soy intake was inversely associated with breast cancer risk in Asian but not Western populations. There is growing evidence that...
high levels of fruit and vegetable consumption may be associated with reduced risk of hormone receptor negative breast cancer.114-116 The effect of diet on breast cancer risk remains an active area of research, with studies particularly focusing on timing of exposure, specific dietary components, and whether risks may differ by tumor hormone receptor status.

Alcohol
Numerous studies have confirmed that alcohol consumption increases the risk of breast cancer in women by about 7% to 12% for each 10g (roughly one drink) of alcohol consumed per day.117-119 The increased risk is dose-dependent and exists regardless of the type of alcoholic beverage consumed.119 One of the mechanisms by which alcohol increases risk of breast cancer is by increasing estrogen and androgen levels.120 Alcohol use has been more strongly related with increased risk for ER+ than ER- breast cancers.121,122

Tobacco
In 2009, the International Agency for Research on Cancer concluded that there was limited evidence that tobacco smoking causes breast cancer in women based on a review of 150 studies.123 A recent meta-analysis by American Cancer Society researchers found that current smokers had a 12% higher risk of breast cancer than women who never smoked.124 Research also suggests that risk may be greater for women who begin smoking before first childbirth.125,126

In 2006, the US Surgeon General characterized the evidence linking secondhand smoke and breast cancer as “suggestive but not sufficient” to infer a causal relationship.127 However, a subsequent meta-analysis concluded that there was no association between secondhand smoke and breast cancer, regardless of the time of onset of exposure. The results of more recent studies have also failed to show a clear relationship between passive smoking and breast cancer risk.124,129,130 Nevertheless, it is clear that avoiding exposure to secondhand smoke has multiple health benefits.

Oral contraceptive use
Recent use of oral contraceptives may increase the risk of breast cancer by about 10% to 30%; however, since most studies have looked at older, high-dose estrogen forms of oral contraceptives, the risk with current, low-dose formulations is not clear.131 Women who have stopped using oral contraceptives for 10 years or more have the same risk as women who never used the pill.131

Other risk factors
Radiation
The link between radiation exposure and breast cancer has been demonstrated in studies of atomic bomb survivors and women who have received high-dose radiation therapy to the chest, particularly for those who were first exposed at younger ages.132,133 This may be because breast tissue is most susceptible to carcinogens before it is fully differentiated, which occurs with first childbirth.134

Breast cancer is one of the most common types of second cancers among childhood cancer survivors. Secondary breast cancer is most strongly associated with high-dose radiation therapy to the chest for women treated between 10 and 30 years of age, such as for Hodgkin lymphoma.135 Breast cancer risk among women with such exposure start to rise about 8 years after radiation treatment and continue to be elevated for more than 25 years.133

Diethylstilbestrol exposure
From the 1940s through the 1960s, some pregnant women were given the drug diethylstilbestrol (DES) because it was thought to lower the risk of miscarriage. These women have increased risk (about 30% higher) of developing breast cancer compared to women who have not taken DES.136 Some studies have found that women whose mothers took DES during pregnancy also have a slightly higher risk of breast cancer.137

Environmental pollutants
Concerns have been raised among some advocacy groups and survivors that rising breast cancer incidence in the latter half of the 20th century may have been caused by environmental pollutants such as organochlorine pesticides. However, studies to date have found no association between increased concentrations of organochlorines in blood and fat tissue and breast cancer risk.138-141

Although animal studies have demonstrated that prolonged, high-dose exposure to many industrial chemicals can increase mammary tumor development, it is difficult to determine whether exposure to much lower concentrations of these chemicals in the general environment – which occur alone or in combination, in air, drinking water, and consumer products – increases the risk of human breast cancer.142 In general, epidemiological studies have not found clear relationships between environmental pollutants and breast cancer, though these studies have had limited capability to study effects on population subgroups or to quantify exposures at potentially critical periods of life, such as adolescence. An association between environmental exposures and breast cancer may be difficult to quantify because it may reflect an indirect pathway (e.g., an effect of these exposures on early onset puberty). This continues to be an active area of research.

Occupational exposures
A few occupations have been linked to breast cancer risk. One study found an increased risk of breast cancer among women employed in commercial sterilization facilities who were exposed to high levels of ethylene oxide.143 This chemical has been shown to cause breast cancer in experimental animals.
Night shift work may also be associated with increased breast cancer risk. Most studies of nurses who work night shifts and flight attendants who experience circadian rhythm disruption caused by crossing multiple time zones have found increased risks of breast cancer associated with long-term employment.\textsuperscript{144,145} Animal studies suggest that exposure to light at night causes circadian rhythm disruption and increases cancer incidence.\textsuperscript{146} Some researchers suggest that the increased risk of breast cancer may be due to decreases in melatonin levels that occur as a result of exposure to light at night; melatonin may affect estrogen levels, as well as act as a tumor suppressor.\textsuperscript{146} Based on the results of studies in humans and experimental animals, the International Agency for Research on Cancer concluded in 2007 that shift work, particularly at night, was probably carcinogenic to humans.\textsuperscript{147} Additional studies are needed to confirm this relationship because shift work at night is a common exposure, involving about 15% to 20% of workers in the US and Europe, and because much of the population in industrialized countries is exposed to artificial light at night.

### Factors that are not associated with breast cancer risk

#### Abortion

There are persistent claims that women who have had an abortion are at increased risk for developing breast cancer based on early studies that have since been deemed methodologically flawed by the American College of Obstetricians and Gynecology.\textsuperscript{148} Indeed, a large body of solid scientific evidence, including a review by a panel of experts convened by the National Cancer Institute in 2003, confirms that there is no link between breast cancer and abortion (either spontaneous or induced).\textsuperscript{149} For more information, see the American Cancer Society document called Is Abortion Linked to Breast Cancer?, which is available at cancer.org.

#### Hair dyes and antiperspirants

A combined analysis of 14 studies found no association between the use of permanent hair dyes and breast cancer.\textsuperscript{150} Although antiperspirant use has been less well-studied, there is presently no conclusive scientific evidence that links breast cancer risk to the use of antiperspirants.\textsuperscript{151,152}

#### Breast implants

No association has been found between breast implants and an increased risk of breast cancer; however, there is growing concern that women with implants may be at increased risk of a rare type of lymphoma.\textsuperscript{153-155}

Breast implants can make it harder to see breast tissue by mammography. A woman with breast implants should inform the mammography facility about the implants when scheduling her mammogram. The use of additional x-ray pictures (called implant displacement views) may be used to allow for more complete breast imaging.

### Chemoprevention and prophylactic surgery

#### Chemoprevention

The use of drugs to reduce the risk of disease is called chemoprevention. Clinical trials have shown that the drugs tamoxifen and raloxifene significantly reduce the risk of breast cancer in women known to be at increased risk.\textsuperscript{156}

Tamoxifen has been used for more than 30 years as a treatment for some breast cancers. In 1998, a large, randomized trial of more than 13,000 women first demonstrated that tamoxifen can also be used to reduce the risk of invasive and in situ ER+ breast cancer in women at high risk for developing the disease.\textsuperscript{157} After an average of 7 years of follow up, breast cancer risk was decreased by 42% in the group that received tamoxifen. A protective effect was also observed in an international randomized prevention trial involving more than 7,000 women.\textsuperscript{158} Long-term follow-up results indicate that the reduction in risk persists after completion of the 5-year treatment schedule.\textsuperscript{158,159} Side effects of tamoxifen include increased risk of endometrial cancer, thromboembolic events, and cataracts.\textsuperscript{156}

Raloxifene’s efficacy in the prevention of breast cancer was discovered by accident. In a study looking at raloxifene for the prevention of osteoporosis, researchers noticed that patients taking raloxifene had a lower risk of breast cancer than the control group.\textsuperscript{160} The Study of Tamoxifen and Raloxifene (STAR) trial, which compared the effectiveness of tamoxifen and raloxifene, found that although raloxifene was somewhat less effective in preventing invasive breast cancer, it was associated with lower risks of certain side effects (endometrial cancer, blood clots in the legs or lungs, and cataracts).\textsuperscript{161} Similar to tamoxifen,
the benefit of raloxifene appears to be limited to reducing the risk of developing ER+ breast cancer. Unlike tamoxifen, raloxifene is only approved for use in postmenopausal women.

Chemoprevention is not appropriate for all women who are eligible because of potential side effects. An estimated 19% of white women and 6% of African American women 35 to 79 years of age are eligible (based on criteria from the US Food and Drug Administration) for chemoprevention, but the benefit would be expected to outweigh the risks for only 5% of white women and about 1% of African American women. However, according to the 2010 National Health Interview Survey, only 0.03% of US women 35 to 79 years of age without a personal history of breast cancer were taking tamoxifen and 0.21% of women 50 to 79 reported using raloxifene.

Clinical trials are also examining another class of drugs — aromatase inhibitors — to see if they may be effective for reducing breast cancer risk. Aromatase inhibitors target the enzyme that is responsible for producing estrogen in the fat tissue. Currently, these drugs are only approved to prevent breast cancer recurrence. Early results are promising: women at moderately increased risk taking exemestane had a 65% lower risk of developing invasive breast cancer after three years compared to women taking a placebo. These drugs are only effective in women without functioning ovaries, such as postmenopausal women. Women taking aromatase inhibitors must be monitored for osteoporosis, as these medications can decrease bone density.

Prophylactic surgery

Women at very high risk of breast cancer may elect prophylactic (preventive) mastectomy. This operation removes one or both breasts before breast cancer has been discovered. Some women may also choose to have their breasts reconstructed after the surgery. Breast reconstruction can be performed at the same time as the mastectomy (immediate reconstruction) or months to years after the mastectomy (delayed reconstruction). There are several techniques for breast reconstruction. The conventional or traditional mastectomy involves removal of the nipple and areolar skin, but some recent studies are demonstrating that selected patients may be able to safely undergo a nipple-sparing mastectomy. However, long-term data regarding the safety of nipple preservation are limited. Removing both breasts before cancer is diagnosed reduces the risk of breast cancer by 90% or more. Prophylactic salpingo-oophorectomy (surgical removal of the fallopian tubes and ovaries) reduces the risk of both breast and ovarian cancers in women who carry BRCA mutations.

It is important to note that not all women who elect to have these surgeries would have developed cancer. A woman considering these operations should discuss this carefully with her doctor. A second opinion is strongly recommended.

Some women who are diagnosed with breast cancer in one breast choose to have the unaffected breast removed as well. This is known as contralateral prophylactic mastectomy (CPM). Recent studies have shown marked increases in the rate of CPM for women diagnosed with invasive breast cancer, as well as DCIS. Although CPM nearly eliminates the risk of developing breast cancer, there is less evidence that it improves long-term breast cancer survival. Studies suggest that a survival advantage may be limited to certain subgroups, such as women diagnosed before 50 years of age and those with ER-positive breast cancers.

Breast Cancer Screening

American Cancer Society guidelines for the early detection of breast cancer vary depending on a woman’s age and include mammography and clinical breast examination (CBE), as well as magnetic resonance imaging (MRI) for women at high risk.

Mammography

Mammography is a low-dose x-ray procedure that allows visualization of the internal structure of the breast. Dedicated mammography units used today result in higher-quality images with a considerably lower x-ray dose than the general-purpose x-ray equipment used in the past. Conventional (film) mammography has been largely replaced by digital mammography, which appears to be even more accurate for women younger than age 50 and for those with dense breast tissue.
lumpectomy versus mastectomy) and the use of chemotherapy with fewer serious side effects, or even, in some cases, the option to forgo chemotherapy. However, mammography screening does have potential harms.

**False-positive results**

Mammography sometimes leads to follow-up examinations, including biopsies, when there is no cancer; these are referred to as false-positive test results. A false-positive is most likely following a woman’s initial screening mammogram. On average, 10% of women will be recalled from each screening examination for further testing, but only 5% of these women will have cancer. According to one US study, over the course of 10 screening examinations, about one-half of women will experience a false-positive, and about 19% will undergo biopsy.

**Overdiagnosis**

Mammography likely results in some overdiagnosis; that is, the detection of cancers that would not have progressed or otherwise been detected unless a woman underwent screening. Since it is not currently possible to distinguish a nonprogressive cancer from a progressive one, overdiagnosis is estimated from long-term evaluation of observed versus expected cases in a screening program. Estimates of the rate of overdiagnosis are highly variable, ranging from 0% to more than 30%.

**Radiation exposure**

Although many people are concerned about radiation exposure, the dose required for a mammogram is very small and the risk of harm is minimal.

**Limitations of mammography**

As with all screening tests, mammography is not 100% effective. Not all breast cancer will be detected by a mammogram, and some breast cancers that are screen-detected still have poor prognosis. Although the lifetime risk of breast cancer is substantial (1 in 8), most women will not be diagnosed with breast cancer in their lifetime, but will undergo regular screening and many will experience one or more “false alarms.” In an effort to maximize the benefits and minimize the harms of screening, some scientists are attempting to determine which combinations of conventional and new risk factors could be used to individualize screening recommendations (e.g., determine which women could start screening at older ages and/or be screened less often).

Despite these limitations, mammography is the single most effective method of early detection since it can often identify cancer several years before physical symptoms develop. It is the position of the American Cancer Society that the balance of benefits to possible harms strongly supports the value of regular breast cancer screening in women who are 40 years of age or older.

According to the American Cancer Society guidelines, there is no specific age at which mammography screening should be discontinued. Rather, the decision to stop regular mammography screening should be individualized based on the potential benefits and risks of screening within the context of overall health status and estimated longevity. As long as a woman is in good health and would be a candidate for breast cancer treatment, she should continue to be screened with mammography.

The Affordable Care Act requires that Medicare and all new health insurance plans fully cover screening mammograms without any out-of-pocket expense for patients. For help locating a free or low-cost screening mammogram in your area, contact the American Cancer Society at 1-800-227-2345.
Prevalence of mammography

According to the National Health Interview Survey, the percentage of women 40 years of age and older who reported having had a mammogram within the past 2 years was 67% in 2010 (Table 6, page 19). Mammography prevalence increased from 29% in 1987 to 70% in 2000, declined slightly (by 3.4%) from 2000 to 2005, and then stabilized. Women who have less than a high school education, who have no health insurance coverage, or who are recent immigrants to the US are least likely to have had a recent mammogram. Similarly, poor and near poor women are less likely to have had a mammogram within the past 2 years than non-poor women, and declines in mammography usage have generally been greater among poorer women (Table 7). Efforts to increase screening should specifically target socioeconomically disadvantaged women and recent immigrants, who are most likely to have the lowest rates of mammographic screening.

Table 8 (page 22) shows the percentage of US women 40 years of age and older who have had a mammogram within the past year by state, based on data from the 2010 Behavioral Risk Factor Surveillance System. Among women 40 years of age and older, reported annual screening rates range from 47% in Wyoming, to 72% in Massachusetts.

The Centers for Disease Control and Prevention’s National Breast and Cervical Cancer Early Detection Program (NBCCEDP) was established in 1990 to improve access to breast cancer screening and diagnostic services for low-income women and was recently shown to save lives from breast cancer. However, the CDC estimates that the program is currently only reaching about 12% of the women eligible to receive a screening mammogram, due in part to funding shortages. The American Cancer Society is committed to helping protect and increase funding for NBCCEDP in order to expand the number of women who can be served through the program.

Magnetic resonance imaging (MRI)

An expert panel convened by the Society published recommendations for the use of MRI for screening women at increased risk for breast cancer in 2007. The panel recommended annual MRI screening in addition to mammography for women at high lifetime risk (~20%-25% or greater) beginning at 30 years of age. Women at moderately increased risk (15%-20% lifetime risk) should talk with their doctors about the benefits and limitations of adding MRI screening to their yearly mammogram. See risk criteria for MRI screening (right). MRI screening is not recommended for women whose lifetime risk of breast cancer is less than 15%.

MRI uses magnetic fields instead of x-rays to produce very detailed, cross-sectional images of the body. MRI exams for breast imaging use a contrast material (usually gadolinium DTPA) that is injected into a vein in the arm before or during the exam to improve the ability to capture detailed images of breast tissue. MRIIs should supplement, but not replace, mammography screening.

Just as mammography uses x-ray machines designed especially to image the breasts, breast MRI also requires special equipment. Higher-quality images are produced by dedicated breast MRI equipment than by machines designed for head, chest, or abdominal MRI scanning. However, many hospitals and imaging centers do not have dedicated breast MRI equipment available. It is important that screening MRIs are done at facilities that are capable of performing an MRI-guided breast biopsy in case abnormalities are found. Otherwise, the scan must be repeated at another facility if a biopsy is necessary. Although MRI is more expensive than mammography, most major insurance companies will cover some portion of the costs if a woman can be shown to be at high risk.

Clinical breast examination (CBE)

For average-risk, asymptomatic women in their 20s and 30s, it is recommended that a breast exam be a part of a regular health examination, preferably at least every 3 years. For women 40 or older, annual CBE can be an important complement to mammography, since a small percentage of cancers may be missed by mammography.
Ideally, women should have their CBE shortly before their annual mammogram. During a CBE, the clinician uses the pads of the fingers to gently feel the breasts, giving special attention to shape, texture, location of any lumps, and whether such lumps are attached to the skin or to deeper tissues. The breasts should also be inspected for skin irregularities (e.g., dimpling, redness) and asymmetry. The area under both arms will also be examined. CBE is also an opportunity for a woman and her health care provider to discuss changes in her breasts and early detection testing, to review and update family history information, and to discuss any questions she may have about breast cancer.

Breast self-awareness

All women should become familiar with both the appearance and feel of their breasts and report any changes promptly to their physician. Although the American Cancer Society no longer recommends that all women perform monthly breast self-exams (BSE), women should be informed about the potential benefits and limitations associated with BSE. Experts have concluded that self-awareness seems to be at least as effective for detecting breast cancer as structured BSE.\(^{196-200}\) Women who detect their own breast cancer usually find it outside of a structured breast self-exam while bathing or getting dressed. A woman who wishes to perform periodic BSE should receive instruction from her health care provider and/or have her technique reviewed periodically.

If symptoms develop, women should contact a doctor immediately, even after a recent normal mammogram. However, lumps are not necessarily abnormal, and for women who are still menstruating, they can appear and disappear with the menstrual cycle. Most breast lumps are not cancerous.

Breast ultrasound

Breast ultrasound is sometimes used to evaluate abnormal findings from a screening or diagnostic mammogram or physical exam. Some studies have suggested that ultrasound may detect more cancer than mammography alone when screening women with dense breast tissue; however, it also increases the likelihood of false-positive results.\(^{201}\) The use of ultrasound instead of mammograms for breast cancer screening is not recommended.

---

Table 7. Mammography Prevalence (%) within the Past Two Years by Age and Poverty Status*, US, Selected Years 1987-2010

<table>
<thead>
<tr>
<th>Year</th>
<th>40-49 years</th>
<th>50-64 years</th>
<th>65 years and over</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Poor</td>
<td>Near poor</td>
<td>Non-poor</td>
</tr>
<tr>
<td>1987</td>
<td>19</td>
<td>18</td>
<td>44</td>
</tr>
<tr>
<td>1990</td>
<td>32</td>
<td>39</td>
<td>69</td>
</tr>
<tr>
<td>1991</td>
<td>33</td>
<td>44</td>
<td>70</td>
</tr>
<tr>
<td>1993</td>
<td>36</td>
<td>48</td>
<td>70</td>
</tr>
<tr>
<td>1994</td>
<td>43</td>
<td>48</td>
<td>70</td>
</tr>
<tr>
<td>1998</td>
<td>45</td>
<td>47</td>
<td>73</td>
</tr>
<tr>
<td>1999</td>
<td>51</td>
<td>53</td>
<td>77</td>
</tr>
<tr>
<td>2000</td>
<td>47</td>
<td>44</td>
<td>76</td>
</tr>
<tr>
<td>2003</td>
<td>51</td>
<td>54</td>
<td>72</td>
</tr>
<tr>
<td>2005</td>
<td>42</td>
<td>50</td>
<td>74</td>
</tr>
<tr>
<td>2008</td>
<td>47</td>
<td>47</td>
<td>73</td>
</tr>
<tr>
<td>2010</td>
<td>48</td>
<td>46</td>
<td>74</td>
</tr>
</tbody>
</table>

*Poor persons are defined as below the poverty threshold. Near poor persons have income of 100%-199% of the poverty threshold. Non-poor persons have an income 400% or more than the poverty level.

Source: Health, United States, 2012.\(^{194}\)

American Cancer Society, Surveillance and Health Services Research, 2013.
## Table 8. Mammography and Clinical Breast Exam, Women 40 and Older, by State, 2012

<table>
<thead>
<tr>
<th>State</th>
<th>% Recent Mammogram*</th>
<th>% Recent Mammogram and Clinical Breast Exam†</th>
<th>% Recent Mammogram*</th>
<th>% Recent Mammogram and Clinical Breast Exam†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No usual source of</td>
<td>No health insurance‡</td>
<td>No usual source of</td>
<td>No health insurance‡</td>
</tr>
<tr>
<td></td>
<td>medical care§</td>
<td></td>
<td>medical care§</td>
<td></td>
</tr>
<tr>
<td></td>
<td>40 years and older</td>
<td></td>
<td>40 years and older</td>
<td></td>
</tr>
<tr>
<td></td>
<td>40 to 64 years</td>
<td></td>
<td>40 to 64 years</td>
<td></td>
</tr>
<tr>
<td></td>
<td>65 years and older</td>
<td></td>
<td>65 years and older</td>
<td></td>
</tr>
<tr>
<td>Alabama</td>
<td>59</td>
<td>58</td>
<td>60</td>
<td>28</td>
</tr>
<tr>
<td>Alaska</td>
<td>54</td>
<td>53</td>
<td>58</td>
<td>35</td>
</tr>
<tr>
<td>Arizona</td>
<td>53</td>
<td>50</td>
<td>60</td>
<td>27</td>
</tr>
<tr>
<td>Arkansas</td>
<td>50</td>
<td>47</td>
<td>54</td>
<td>29</td>
</tr>
<tr>
<td>California</td>
<td>59</td>
<td>57</td>
<td>62</td>
<td>29</td>
</tr>
<tr>
<td>Colorado</td>
<td>52</td>
<td>51</td>
<td>56</td>
<td>22</td>
</tr>
<tr>
<td>Connecticut</td>
<td>66</td>
<td>67</td>
<td>64</td>
<td>28</td>
</tr>
<tr>
<td>Delaware</td>
<td>68</td>
<td>66</td>
<td>70</td>
<td>–</td>
</tr>
<tr>
<td>District of Columbia</td>
<td>63</td>
<td>62</td>
<td>65</td>
<td>–</td>
</tr>
<tr>
<td>Florida</td>
<td>59</td>
<td>55</td>
<td>65</td>
<td>28</td>
</tr>
<tr>
<td>Georgia</td>
<td>62</td>
<td>59</td>
<td>70</td>
<td>33</td>
</tr>
<tr>
<td>Hawaii</td>
<td>59</td>
<td>59</td>
<td>59</td>
<td>36</td>
</tr>
<tr>
<td>Idaho</td>
<td>49</td>
<td>46</td>
<td>55</td>
<td>21</td>
</tr>
<tr>
<td>Illinois</td>
<td>58</td>
<td>57</td>
<td>60</td>
<td>–</td>
</tr>
<tr>
<td>Indiana</td>
<td>52</td>
<td>50</td>
<td>57</td>
<td>18</td>
</tr>
<tr>
<td>Iowa</td>
<td>61</td>
<td>60</td>
<td>63</td>
<td>35</td>
</tr>
<tr>
<td>Kansas</td>
<td>60</td>
<td>60</td>
<td>61</td>
<td>30</td>
</tr>
<tr>
<td>Kentucky</td>
<td>57</td>
<td>56</td>
<td>59</td>
<td>26</td>
</tr>
<tr>
<td>Louisiana</td>
<td>60</td>
<td>60</td>
<td>61</td>
<td>37</td>
</tr>
<tr>
<td>Maine</td>
<td>65</td>
<td>65</td>
<td>66</td>
<td>24</td>
</tr>
<tr>
<td>Maryland</td>
<td>65</td>
<td>64</td>
<td>66</td>
<td>38</td>
</tr>
<tr>
<td>Massachusetts</td>
<td>72</td>
<td>72</td>
<td>72</td>
<td>40</td>
</tr>
<tr>
<td>Michigan</td>
<td>59</td>
<td>58</td>
<td>62</td>
<td>21</td>
</tr>
<tr>
<td>Minnesota</td>
<td>63</td>
<td>61</td>
<td>68</td>
<td>39</td>
</tr>
<tr>
<td>Mississippi</td>
<td>52</td>
<td>51</td>
<td>55</td>
<td>27</td>
</tr>
<tr>
<td>Missouri</td>
<td>58</td>
<td>56</td>
<td>64</td>
<td>25</td>
</tr>
<tr>
<td>Montana</td>
<td>50</td>
<td>49</td>
<td>53</td>
<td>19</td>
</tr>
<tr>
<td>Nebraska</td>
<td>54</td>
<td>54</td>
<td>55</td>
<td>26</td>
</tr>
<tr>
<td>Nevada</td>
<td>50</td>
<td>48</td>
<td>54</td>
<td>28</td>
</tr>
<tr>
<td>New Hampshire</td>
<td>65</td>
<td>64</td>
<td>67</td>
<td>–</td>
</tr>
<tr>
<td>New Jersey</td>
<td>61</td>
<td>62</td>
<td>60</td>
<td>41</td>
</tr>
<tr>
<td>New Mexico</td>
<td>50</td>
<td>48</td>
<td>53</td>
<td>25</td>
</tr>
<tr>
<td>New York</td>
<td>62</td>
<td>63</td>
<td>61</td>
<td>42</td>
</tr>
<tr>
<td>North Carolina</td>
<td>62</td>
<td>59</td>
<td>67</td>
<td>29</td>
</tr>
<tr>
<td>North Dakota</td>
<td>58</td>
<td>56</td>
<td>61</td>
<td>–</td>
</tr>
<tr>
<td>Ohio</td>
<td>60</td>
<td>59</td>
<td>63</td>
<td>28</td>
</tr>
<tr>
<td>Oklahoma</td>
<td>52</td>
<td>51</td>
<td>55</td>
<td>24</td>
</tr>
<tr>
<td>Oregon</td>
<td>54</td>
<td>50</td>
<td>62</td>
<td>–</td>
</tr>
<tr>
<td>Pennsylvania</td>
<td>60</td>
<td>59</td>
<td>62</td>
<td>28</td>
</tr>
<tr>
<td>Rhode Island</td>
<td>67</td>
<td>66</td>
<td>70</td>
<td>–</td>
</tr>
<tr>
<td>South Carolina</td>
<td>54</td>
<td>52</td>
<td>60</td>
<td>25</td>
</tr>
<tr>
<td>South Dakota</td>
<td>62</td>
<td>61</td>
<td>62</td>
<td>37</td>
</tr>
<tr>
<td>Tennessee</td>
<td>57</td>
<td>55</td>
<td>60</td>
<td>28</td>
</tr>
<tr>
<td>Texas</td>
<td>54</td>
<td>51</td>
<td>60</td>
<td>23</td>
</tr>
<tr>
<td>Utah</td>
<td>50</td>
<td>49</td>
<td>53</td>
<td>30</td>
</tr>
<tr>
<td>Vermont</td>
<td>61</td>
<td>61</td>
<td>63</td>
<td>–</td>
</tr>
<tr>
<td>Virginia</td>
<td>64</td>
<td>64</td>
<td>65</td>
<td>42</td>
</tr>
<tr>
<td>Washington</td>
<td>56</td>
<td>53</td>
<td>61</td>
<td>28</td>
</tr>
<tr>
<td>West Virginia</td>
<td>58</td>
<td>58</td>
<td>59</td>
<td>25</td>
</tr>
<tr>
<td>Wisconsin</td>
<td>63</td>
<td>61</td>
<td>68</td>
<td>–</td>
</tr>
<tr>
<td>Wyoming</td>
<td>47</td>
<td>46</td>
<td>51</td>
<td>27</td>
</tr>
<tr>
<td>United States</td>
<td>59</td>
<td>58</td>
<td>61</td>
<td>28</td>
</tr>
<tr>
<td>Range</td>
<td>47-72</td>
<td>46-72</td>
<td>51-72</td>
<td>18-42</td>
</tr>
</tbody>
</table>

* A mammogram within the past year. † Both a mammogram and clinical breast exam within the past year. ‡ Women who reported that they did not have a personal doctor or health care provider. § Women ages 40 to 64 who reported that they did not have any kind of health care coverage.

**Source:** Behavioral Risk Factor Surveillance System (BRFSS) 2012, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention. Statistic not shown if based on fewer than 50 respondents. Note: The 2012 BRFSS cancer screening data results should be considered baseline and are not directly comparable to previous years of BRFSS data because of the changes in weighting methodology and the addition of the cell phone sampling frame.

American Cancer Society, Surveillance and Health Services Research, 2013
Breast Cancer Treatment

Treatment decisions are made by the patient and the physician after consideration of the optimal treatment available for the stage and biological characteristics of the cancer, the patient’s age and preferences, and the risks and benefits associated with each treatment protocol. Most women with breast cancer will have some type of surgery. Surgery is often combined with other treatments such as radiation therapy, chemotherapy, hormone therapy, and/or targeted therapy.

Surgery

The primary goals of breast cancer surgery are to remove the cancer from the breast and to determine the stage of disease. Surgical treatment for breast cancer involves breast-conserving surgery (BCS) or mastectomy. With BCS (also known as partial mastectomy, quadrantectomy, and lumpectomy), only cancerous tissue plus a rim of normal tissue are removed. Simple or total mastectomy includes removal of the entire breast. Modified radical mastectomy includes removal of the entire breast and lymph nodes under the arm, but does not include removal of the underlying chest wall muscle, as with a radical mastectomy. Radical mastectomy is rarely used because in most cases removal of the underlying chest muscles is not needed to remove all of the cancer.

Fifty-seven percent of women diagnosed with early stage (I or II) breast cancer have BCS, 36% have mastectomy, 6% have no surgery, and about 1% do not receive any treatment (Figure 10, page 24). In contrast, among women with late-stage (III or IV) breast cancer, 13% undergo BCS, 60% have mastectomy, 18% have no surgical treatment, and 7% do not receive any treatment (Figure 10, page 24).

Depending on age at diagnosis, 20%-40% of women who undergo mastectomy elect to have breast reconstruction, either with an implant, tissue from another part of the body, or a combination of the two. A woman considering breast reconstruction should discuss this option with her breast surgeon prior to her mastectomy. The plastic surgeon and the surgeon performing the mastectomy will work together to coordinate treatment plans. Some types of reconstruction can begin during the mastectomy itself, so reconstruction may influence the surgical facility (inpatient versus outpatient) and other aspects of the mastectomy. Since 1999, the Women’s Health and Cancer Rights Act (WHCRA) has required group health plans, insurance companies, and health maintenance organizations that offer mastectomy coverage to also pay for reconstructive surgery after mastectomy for breast cancer. Reconstruction is also covered by Medicare and Medicaid, though Medicaid benefits vary by state.

Both BCS and mastectomy are usually accompanied by removal of regional lymph nodes from the armpit to determine if the disease has spread beyond the breast. The presence of any cancer cells in the lymph nodes will help determine the need for subsequent therapy and the course it should take. Sentinel lymph node biopsy (SLNB), in which selected lymph nodes are removed and tested before any others are excised, reduces the need for full axillary lymph node dissections among most women with no evidence of sentinel lymph node involvement. Furthermore, findings from a recent clinical trial suggest that for some breast cancer patients treated by lumpectomy and radiation, the axillary lymph node dissection can be avoided even if cancer cells are found in one or two sentinel lymph nodes. Prior to surgery, patients should talk with their doctors to determine whether they intend to perform SLNB. If a woman is eligible for SLNB and wishes to have this procedure, her breast cancer surgery should be performed at a facility with a medical care team experienced with the technique. SLNB is widely available in the US.

Surgery and radiation therapy involving the axillary lymph nodes can lead to lymphedema, a serious swelling of the arm caused by retention of lymph fluid. Breast cancer patients who undergo axillary lymph node dissection are about 3 times more likely to develop lymphedema compared to those who have SLNB. It has been estimated that about 5% of patients with SLNB and 16%-18% of patients undergoing axillary lymph node dissection following SLNB will develop clinically measurable lymphedema. Some evidence suggests that upper body exercises may reduce the risk and lessen the severity of this condition.

Radiation therapy

Radiation therapy is the use of high-energy beams or particles to kill cancer cells. Radiation may be used after potentially curative surgery to destroy cancer cells remaining in the breast, chest wall, or underarm area. BCS is almost always followed by radiation therapy because it has been shown to reduce the risk of cancer recurrence by about 50% and the risk of breast cancer death by about 20%. Although there is a higher risk of local recurrence (cancer returning to the breast) with BCS, clinical trials with more than 20 years of follow-up data have confirmed that a woman who chooses BCS and radiation will have the same expected long-term survival as if she had chosen mastectomy. Some mastectomy patients also require radiation if their tumor is larger than 5 cm or when cancer is found in the lymph nodes. Radiation can also be used to treat the symptoms of advanced breast cancer, especially when it has spread to the central nervous system or bones.
Radiation therapy may be administered internally or externally. Some patients are treated with both types of radiation in combination. The way the radiation therapy is given depends on the type, stage, and location of the tumor, as well as doctor and patient preference.

External beam radiation is the standard type of radiation for women with breast cancer. Radiation is focused from a machine outside the body on the area affected by cancer. This usually includes the whole breast and, depending on the size and extent of the cancer, may include the chest wall and underarm area as well. External beam radiation therapy is typically administered daily over a period of 5 to 6 weeks; however, in recent studies, shortening the treatment to 3 weeks (referred to as accelerated breast irradiation or ABI) appears to be just as effective.

Internal radiation therapy, known as brachytherapy, is a form of accelerated partial breast irradiation (APBI) which uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer. The ability to target radiation therapy accurately has increased dramatically in recent decades, which has greatly diminished side effects and can also reduce treatment time. Internal radiation therapy is given for only 5 days. For example, the most common form of brachytherapy used for breast cancer, intracavitary brachytherapy, is given for only 5 days.

Clinical trials are also investigating other forms of APBI that are designed to give radiation to a smaller segment of the breast, also over a period of 5 days.

**Systemic therapy**

Systemic therapy is treatment that travels through the bloodstream and affects all parts of the body, not just the cancer. These cancer drugs are injected into a vein or given by mouth. Systemic therapy includes chemotherapy, hormone therapy, and targeted therapy, all of which work through different mechanisms. For example, chemotherapy drugs work by attacking cells that grow quickly, such as cancer cells. Hormone therapy works by either blocking the body’s natural hormones or lowering the levels of those hormones, which sometimes act to promote cancer growth. Newer targeted drugs work by attacking specific parts of cancer cells.

When systemic treatment is given to patients before surgery, it is called neoadjuvant therapy. It is often used to shrink the tumor enough to make surgical removal possible or allow for less extensive surgery (such as BCS in women who would otherwise have required mastectomy). Neoadjuvant systemic therapy has been found to be as effective as therapy given after surgery in terms of survival, disease progression, and distant recurrence.

Systemic treatment given to patients after surgery is called adjuvant therapy. It is used to kill any undetected tumor cells that were left behind during surgery or had migrated to other parts of the body. The use of adjuvant systemic therapy is primarily determined by the tumor stage and histopathological characteristics (hormone receptor and HER2 status).
Systemic therapy is the main treatment option for women with metastatic breast cancer who may not benefit from surgery due to the extensive spread of the disease.

Chemotherapy
The benefit of chemotherapy is dependent on multiple factors, including the size of the cancer, the number of lymph nodes involved, the presence of estrogen or progesterone receptors, and the amount of HER2 protein made by the cancer cells. Basal-like and HER2-enriched breast cancers tend to be more sensitive to chemotherapy, while luminal A tumors are generally less responsive.225

Research has established that in most cases, combinations of drugs are more effective than one drug alone for breast cancer treatment. Many combinations are being used, and it is not clear that any single combination is the best. Depending on the combination of drugs used, chemotherapy is usually given for 3 to 6 months. Chemotherapy is most effective when the full dose and cycle of drugs are completed in a timely manner.

Hormone therapy
Estrogen, a hormone produced by the ovaries, promotes the growth of many breast cancers. Women whose breast cancers test positive for estrogen or progesterone receptors can be given hormone therapy to lower estrogen levels or to block the effects of estrogen on the growth of breast cancer cells. Tamoxifen and toremifene (Fareston) are drugs that prevent estrogen from binding to breast cancer cells and are effective in both postmenopausal and premenopausal women. Treatment of ER+ breast cancer with tamoxifen for 5 years has been shown to reduce the rate of recurrence by 39% throughout the first decade, and reduces breast cancer mortality by about one-third throughout the first 15 years.226 Recently released results of the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) study showed that extended use of tamoxifen (10 years versus 5 years) may further reduce the risk of breast cancer recurrence and mortality.227 Fulvestrant (Faslodex) is a newer drug (given by injection once a month) that blocks estrogen binding and then reduces the number of estrogen receptors on breast tumors. It is often effective in postmenopausal women even if the breast cancer is no longer responding to tamoxifen.

Premenopausal women with hormone-sensitive tumors may also benefit from the removal or suppression of the ovaries (ovarian ablation), which are the main source of estrogen prior to menopause. Ovarian ablation may also allow some other hormone therapies to work better.228 Permanent ovarian ablation can be done by surgically removing the ovaries (oophorectomy). More often, potentially reversible ovarian ablation is achieved with a class of drugs called luteinizing hormone-releasing hormone (LHRH) analogs (e.g., goserelin [Zoladex] or leuprolide [Lupron]). Studies have shown that the addition of these drugs to tamoxifen and/or chemotherapy reduces the risk of breast cancer recurrence and death among premenopausal women with early stage, hormone-sensitive breast cancer.229

Aromatase inhibitors (AIs), such as letrozole, anastrozole, and exemestane, are another class of drugs that are used to treat both early and advanced hormone receptor positive breast cancer in postmenopausal women. They work by interfering with the body’s ability to produce estrogen. AIs are not usually an effective treatment in women with functioning ovaries (including premenopausal women). Clinical trials have demonstrated a clear advantage to using either an AI instead of tamoxifen for a total of 5 years or switching to an AI after at least 2 to 3 years of tamoxifen, compared to tamoxifen alone for 5 years.230

In 2010, clinical guidelines were issued recommending that AIs be included in the treatment of postmenopausal women with hormone receptor positive breast cancer.231 Clinical trials continue to assess the optimal timing and duration of treatment. Although AIs have fewer serious side effects than tamoxifen, they can cause osteoporosis (with resulting bone fractures), joint pain, and other musculoskeletal symptoms because they completely deplete postmenopausal women of estrogen.

Targeted therapy
Therapy aimed at HER2
Approximately 15% to 20% of breast cancers overproduce the growth-promoting protein HER2.12 These tumors tend to grow faster and are generally more likely to recur than tumors that do not overproduce HER2. Trastuzumab (Herceptin) is a monoclonal antibody that directly targets the HER2 protein. The combined results of two large trials indicate that adding trastuzumab to standard chemotherapy for early stage HER2-positive breast cancer reduces the risk of recurrence and death by 52% and 33%, respectively, compared to chemotherapy alone.232 This drug is also a standard part of the treatment for advanced (metastatic) HER2-positive breast cancer. In 2006, the US Food and Drug Administration (FDA) approved trastuzumab for all HER2-positive breast cancers. All invasive breast cancers should be tested for the HER2 gene amplification or protein overexpression in order to identify women who would benefit from this therapy. Guidelines were released in 2007 aimed at improving the accuracy of HER2 testing.233

Like trastuzumab, pertuzumab is a monoclonal antibody that attaches to the HER2 protein, though it seems to target a different location. This drug is used to treat HER2-positive, metastatic breast cancer. When given along with docetaxel (Taxotere) and trastuzumab to patients who have not yet received chemotherapy, it has been shown to cause tumors to shrink or stop growing for about 6 months longer than giving docetaxel and trastuzumab alone.234
Another drug, ado-trastuzumab emtansine (Kadcyla, formerly called TDM-1), was recently approved by the FDA to treat HER2-positive metastatic breast cancer, and has been shown to shrink tumors and extend survival. It is made up of the same monoclonal antibody found in trastuzumab attached to a chemotherapy drug known as DM-1. The antibody acts as a homing device, taking the chemotherapy drug directly to the cancer cells.235

Lapatinib (Tykerb) is another drug that has been found to be effective in delaying disease progression in women with HER2-positive advanced breast cancers that have become resistant to trastuzumab.236

Other targeted drugs
Everolimus (Afinitor) is a type of targeted therapy that blocks mTOR, a protein that promotes cell growth and division. By blocking this protein, everolimus can help stop cancer cells from growing. Everolimus may also stop tumors from developing new blood vessels, which can also limit growth. This drug seems to improve the effectiveness of hormone therapy drugs in treating breast cancer. Everolimus was recently approved to treat advanced, hormone receptor-positive, HER2-negative breast cancer in postmenopausal women. It is meant to be used with exemestane in those women whose cancers have grown while they were being treated with either letrozole or anastrozole. Everolimus is also being studied in combination with other hormone therapy drugs.237,238

Bevacizumab (Avastin) is a drug that targets the vascular endothelial growth factor (VEGF) protein, which helps tumors form new blood vessels. After granting accelerated approval of bevacizumab (Avastin) for the treatment of HER2-negative, metastatic breast cancer in 2008, the FDA revoked approval of the drug in November 2011 based on subsequent studies that demonstrated minimal benefit combined with some potentially dangerous side effects.

Clinical trials
A clinical trial is an experiment that is used to assess the safety and efficacy of treatments or other interventions for human disease and health problems. Generally, participants receive either the state-of-the-art standard treatment or a new therapy that may offer improved survival and/or fewer side effects. Participation in clinical trials provides essential information on the effectiveness and risks of a new treatment. For more information about clinical trials, including how to enroll, call the American Cancer Society at 1-800-303-5691 or visit cancer.org/clinicaltrials. Information can also be obtained by visiting the National Cancer Institute’s Web site at cancer.gov/clinicaltrials or by calling 1-800-4-CANCER. Patients should consult their personal doctors and cancer specialists for detailed information about appropriate treatment options.

What is the American Cancer Society doing about breast cancer?
The American Cancer Society works relentlessly to save lives from breast cancer by helping people stay well and get well, by finding cures, and by fighting back against the disease. This section provides highlights and information on some of these efforts.

Stay Well and Get Well
The American Cancer Society helps women stay well by encouraging them to take steps to reduce the risk of breast cancer or detect it early, when there are more treatment options. For women who are diagnosed with breast cancer, the Society provides the information, day-to-day help, and emotional support to guide them through every step of their experience and to help them get well.

Information, 24 Hours a Day, Seven Days a Week
Help and information are available 24 hours a day, seven days a week online at cancer.org and by calling the American Cancer Society at 1-800-227-2345. Callers are connected with a Cancer Information Specialist who can help them locate a hospital, understand breast cancer and treatment options, learn what to expect and how to plan, address insurance concerns, find financial resources, find a local support group, and more. The Society can also help people who speak languages other than English or Spanish find the assistance they need, offering services in 150 languages in total.

Information on every aspect of the breast cancer experience, from prevention to survivorship, is also available at cancer.org/breastcancer. The Society also publishes a wide variety of pamphlets and books that cover a multitude of topics, from patient education, quality-of-life and caregiving issues to healthy living. A complete list of Society books is available for order at cancer.org/bookstore.

Day-to-day Help and Emotional Support
The American Cancer Society offers patients and their families the resources they need to guide them through every step of the breast cancer experience so they can focus on getting well.
Breast cancer support
Breast cancer survivors provide one-on-one support, information, and inspiration to help people facing the disease cope with breast cancer through the American Cancer Society Reach To Recovery® program. Volunteer survivors are trained to respond in person or by telephone to people facing breast cancer diagnosis, treatment, recurrence, or recovery.

Support during treatment
When women are in active breast cancer treatment, they want to look their best, and Look Good Feel Better® helps them do just that. The free program, which is a collaboration of the American Cancer Society, the Personal Care Products Council Foundation, and the Professional Beauty Association, helps women learn beauty techniques to restore their self-image and cope with appearance-related side effects of breast cancer treatment. Certified beauty professionals, trained as Look Good Feel Better volunteers, provide tips on makeup, skin care, nail care, and head coverings. Information and materials are also available for men and teens.

Transportation to treatment
Breast cancer patients cite transportation to and from treatment as a critical need, second only to direct financial assistance. The American Cancer Society Road To Recovery® program matches these patients with specially trained volunteer drivers. In addition, the program offers patients the benefit of companionship and moral support during the drive to medical appointments. In those cases where a Road To Recovery driver isn’t available, the Society may be able to provide other transportation assistance.

Lodging during treatment
When a woman diagnosed with breast cancer must travel away from home for the best treatment, where to stay and how to afford accommodations are immediate concerns and can sometimes affect treatment decisions. American Cancer Society Hope Lodge® facilities provide free, home-like temporary lodging for patients and their caregivers close to treatment centers, thereby easing the emotional and financial burden of finding affordable lodging.

Finding hope and inspiration
Women with breast cancer and their loved ones do not have to face their cancer experience alone. They can connect with others who have “been there” through the American Cancer Society Cancer Survivors Network®. The online community is a welcoming and safe place that was created by and for cancer survivors and their families.

Hair-loss and mastectomy products
Some women wear wigs, hats, breast forms, and bras to help cope with the effects of mastectomy and hair loss. The American Cancer Society “tlc” Tender Loving Care®, which is a magazine and catalog in one, offers helpful articles and a line of products to help women battling cancer restore their appearance and dignity at a difficult time. All proceeds from product sales go back into the Society’s programs and services for patients and survivors.

Cancer education materials
Women with breast cancer and their caretakers need help coping with the challenges of living with the disease. Doctors, nurses, social workers, and other health care professionals can help guide patients and their families through their cancer journey using the American Cancer Society I Can Cope® educational materials. Free classes are also available online at cancer.org/ onlineclasses.

Support after Treatment
The end of breast cancer treatment does not mean the end of a cancer journey. Cancer survivors may experience long-term or late effects resulting from the disease or its treatment. The Life After Treatment guide may help cancer survivors as they begin the next phase of their journey. The free guide can be downloaded at cancer.org/survivorshipguide.

Find Cures
The American Cancer Society, the largest nongovernmental, not-for-profit funding source of cancer research and training in the United States, invests more in breast cancer research than any other cancer type. From 1971 to 2010, the Society awarded approximately $450.7 million in research and training grants associated with the disease. Recently, the Society changed how it reports dollars committed to funding research and training by cancer types. Since 2011, the Society has awarded $46.4 million in breast cancer research and training grants. Society-funded research has led to the development of lifesaving breast cancer drugs such as tamoxifen and Herceptin, as well as the discovery of genes linked to breast cancer (e.g., BRCA1).

The Society is currently funding $86 million in breast cancer research through 220 research and training grants. These grants are awarded in multiple areas relevant to the disease, including genetics, etiology, diagnostics (imaging and biomarkers), drug development; and preclinical, clinical, and epidemiological studies in prevention, diagnosis, treatment, and quality of life.

Specific examples of ongoing breast cancer research being conducted by Society grantees include:

- Establishing an animal model for triple negative breast cancers that are resistant to chemotherapy in order to evaluate new targeted therapies
- Identifying the unmet needs of African American breast cancer survivors in order to develop a program to support and assist in meeting those unique needs
- Evaluating whether known genetic factors for established risk factors, such as age at menarche and height, are associated with breast cancer risk
• Identifying factors associated with joint pain resulting from aromatase inhibitor therapy and investigating ways that it can be effectively managed
• Exploring new therapies for the treatment of breast cancer that activate cells of the immune system and evaluating whether the immune system plays a role in inflammatory responses that promote cancer progression
• Evaluating factors that influence mammography interpretation by radiologists, developing a test set that identifies radiologists who could benefit from additional training, and creating a continuing medical education course that reduces recall rates while maintaining or improving cancer detection. This project, co-funded by the National Cancer Institute, was designed in direct response to the Institute of Medicine’s report “Improving Breast Imaging Quality Standards,” which highlighted the need to decrease variability in mammography interpretation in the US and identified issues stalling the reauthorization of the Mammography Quality Standards Act.

The Society also internally conducts epidemiologic studies of breast cancer and performs surveillance research to monitor racial and socioeconomic disparities in breast cancer screening, incidence, survival, and mortality. Using information collected from more than 600,000 women in the Cancer Prevention Study II (CPS-II), American Cancer Society epidemiologists study the influence of many risk factors, including alcohol consumption, diethylstilbestrol (DES), estrogen hormone use, family history of cancer, obesity, smoking, and spontaneous abortion on the risk of death from breast cancer. Recently published papers have also examined the effect of smoking, weight loss, and vitamin D levels on breast cancer risk. The Society is enrolling cancer-free adults in the Cancer Prevention Study-3 (CPS-3) through December 2013, with the goal of 300,000 participants. This multiyear survey will study lifestyle, behavioral, environmental, and genetic factors that may cause or prevent cancer, with the ultimate goal of eliminating cancer as a major health problem for this and future generations.

American Cancer Society epidemiologists have also studied the influence of mammography on breast cancer prognostic factors, conducted long-term follow up of major breast cancer screening studies, modeled the cost-effectiveness of chemoprevention strategies, and recommended breast cancer surveillance strategies that can be applied at the local and national levels.

The Society’s Behavioral Research Center is currently conducting a study of survivors of 10 cancers, including breast cancer, to examine the determinants of good quality of life. Specific areas of research include healthy lifestyle behaviors (e.g., diet, physical activity, and smoking), body image issues, sexuality and intimacy, and overall quality of life among breast cancer survivors and their caregivers. One recent analysis of this survey found that although the majority of breast cancer survivors 70 years of age and older were reportedly doing well, a subset of survivors had ongoing concerns about symptoms, comorbidities, emotional health, and the lack of social support.

The Society’s Surveillance and Health Services Research group recently reported that breast cancer incidence rates have stabilized among white women in the US, following the sharp drop in rates related to declines in use of menopausal hormones. Another study found that breast cancer ER status varies among African American women depending on region of birth, with higher rates found among Western African-born and Jamaican-born African Americans compared to Eastern African-born African American women. This group also published findings that African American breast cancer patients are less likely than whites to receive recommended breast cancer care, even after controlling for insurance and socioeconomic factors.

**Fight Back**

The American Cancer Society and its nonprofit, nonpartisan advocacy affiliate, the American Cancer Society Cancer Action Network℠ (ACS CAN), are involved in advocacy efforts at both the federal and state levels that seek to increase access to quality breast cancer screenings, diagnostic services and treatment, and care for all women; increase government funding for breast cancer research; and provide a voice for the concerns of breast cancer patients and survivors. Below are some of the efforts that the Society and ACS CAN have been involved with in the past few years to fight back against breast cancer – and all cancers:

• **Improving Access to Affordable Care through Health Care Reform:** The Affordable Care Act (ACA) was signed into law on March 23, 2010, giving cancer patients access to quality, affordable health care. As of 2011, all new health insurance plans and Medicare are required to cover preventive services rated “A” or “B” by the US Preventive Services Task Force (USPSTF), including mammography screening, at no cost to patients. This requirement will be extended in 2014 to cover all insurance companies enrolled in state health insurance exchanges and individuals newly covered through the ACA’s expansion of Medicaid.

• **The National Breast and Cervical Cancer Early Detection Program (NBCCEDP):** Protecting and increasing funding for the NBCCEDP is a high priority for the Society and ACS CAN at both the state and federal levels. This successful program provides community-based breast and cervical cancer screenings to low-income, uninsured, and underinsured women. More than 50% of the women screened are from racial/ethnic minority groups. While the Affordable Care Act will greatly improve insurance coverage, the NBCCEDP will remain an essential program for our nation’s most vulnerable populations. Unfortunately, funding has been cut for the program. In 2013, federal funding was reduced by 10% compared to 2012 due to sequestration and other federal funding cuts,
which will result in tens of thousands of fewer cancer screenings. ACS CAN is asking Congress to increase funding to the full $275 million the program was authorized for in 2007 to ensure that more women have access to cancer screening.

- **Protecting the Breast and Cervical Cancer Prevention and Treatment Act:** This act ensures that low-income women diagnosed with cancer through the NBCCEDP are eligible for Medicaid coverage for treatment. ACS CAN continues to advocate at the state level to protect Medicaid dollars so that there is sufficient funding for treatment of these women.

- **Patient Navigation:** Patient navigation is a critical component in reducing breast cancer deaths and improving quality of care, particularly in vulnerable populations. ACS CAN supports the Patient Navigation Assistance Act, which would create a coverage solution that incentivizes providers to use patient navigators; the end result will be better team-based care coordination for patients with cancer and other chronic illnesses. The organization also supports funding for patient navigator programs and is working with Congress and federal agencies to help increase funding for grant programs for patient navigation.

- **Funding for Cancer Research:** The Society and ACS CAN continue to work to increase government funding for cancer research at the National Institutes of Health, including the National Cancer Institute and the National Center on Minority Health and Health Disparities.

### Additional Resources

**ABCD After Breast Cancer Diagnosis**
Toll-free number: 1-800-977-4121
Web site: abcdbreastcancersupport.org

ABCD provides free, personalized information and one-to-one support to people affected by breast cancer – patients, families, and friends.

**Living Beyond Breast Cancer**
Toll-free number: 1-888-753-5222
Web site: lbbc.org

This nonprofit organization is dedicated to empowering all women affected by breast cancer to live as long as possible with the best quality of life.

**National Breast and Cervical Cancer Early Detection Program**
Toll-free number: 1-800-CDC-INFO or 1-800-232-4636
Web site: cdc.gov/cancer/nbccedp/

This Centers for Disease Control and Prevention (CDC) program helps low-income women gain access to timely, high-quality screening programs for the detection of breast and cervical cancer.

**Sisters Network**
Toll-free number: 1-866-781-1808
Web site: sistersnetworkinc.org

This national African American breast cancer survivor’s support group is committed to increasing local and national attention to the devastating impact that breast cancer has in the African American community.

### Sources of Statistics

**General information.** Unless otherwise stated, the statistics and statements in this booklet refer to invasive (not in situ) breast cancer.

**Estimated new cancer cases.** The estimated numbers of new US cancer cases are projected using a spatiotemporal model based on incidence data from 49 states and the District of Columbia for the years 1995-2009 that met the North American Association of Central Cancer Registries’ (NAACCR) high-quality data standard for incidence, which covers about 98% of the US population. This method considers geographic variations in sociodemographic and lifestyle factors, medical settings, and cancer screening behaviors as predictors of incidence, as well as accounting for expected delays in case reporting.

**Incidence rates.** Incidence rates are defined as the number of people per 100,000 who develop a disease during a given time period. Breast cancer incidence rates for the US in the most recent time period were calculated using data on cancer cases collected by the North American Association of Central Cancer Registries (NAACCR) and population data collected by the US Census Bureau. When referenced as such, NAACCR incidence data were made available on the NAACCR Web site (naaccr.org) and within the Cancer in North America publications. Long-term incidence trends are based on American Cancer Society analysis of the SEER 9 Registries Public Use Dataset, 1973-2010, November 2012 submission, using SEER*Stat 8.0.4, a statistical software package from the National Cancer Institute. Short-term trends (2006-2010) are based on incidence rates from the SEER 13 registries. When referenced as such, US SEER incidence rates and trends were previously made available on SEER’s Web site (seer.cancer.gov) and within the SEER Cancer Statistics Review 1975-2010. Note that because of delays in reporting newly diagnosed cancer cases to the cancer registries, cancer incidence rates for the most recent diagnosis years may be underestimated. Incidence rates adjusted for delays in reporting are used when available and are referenced as such.
Estimated cancer deaths. The estimated number of breast cancer deaths in the US is calculated by fitting the numbers of breast cancer deaths for 1995-2009 to a statistical model that forecasts the numbers of deaths expected to occur in 2013. Data on the number of deaths are obtained from the National Center for Health Statistics (NCHS) at the Centers for Disease Control and Prevention.

Mortality rates. Similar to incidence rates, mortality rates are defined as the number of people per 100,000 who die from a disease during a given time period. Death rates used in this publication were previously made available by SEER on their Web site (seer.cancer.gov) and within the SEER Cancer Statistics Review 1975-2010.14 Death rates were calculated using data on cancer deaths compiled by NCHS and population data collected by the US Census Bureau. All death rates in this publication were age-adjusted to the 2000 US standard population.

Survival. Five-year survival statistics are based on cancer patients diagnosed during 2003-2009; 10-year survival rates are based on diagnoses during 1997-2009; and 15-year survival rates are based on diagnoses during 1992-2009. All patients were followed through 2010. Relative survival rates are used to adjust for normal life expectancy (and events such as death from heart disease, accidents, and diseases of old age). Relative survival is calculated by dividing the percentage of observed 5-year survival for cancer patients by the 5-year survival expected for people in the general population who are similar to the patient group with respect to age, sex, race, and calendar year of observation. Relative survival rates are not calculated for Hispanics/Latinas, Asians/Pacific Islanders, and American Indians/Alaska Natives because reliable estimates of normal life expectancy are not available for these groups; therefore, cause-specific survival rates are presented. Cause-specific survival rates are the probability of not dying of breast cancer within 5 years after diagnosis. Cause-specific survival does not account for stage and age at diagnosis. When referenced as such, 5-year survival statistics were originally published in SEER Cancer Statistics Review, 1975-2010.14

Probability of developing cancer. Probabilities of developing breast cancer were calculated using DevCan (Probability of Developing Cancer Software), developed by the National Cancer Institute. These probabilities reflect the average experience of women in the US and do not take into account individual behaviors and risk factors (e.g., utilization of mammography screening and family history of breast cancer).

Screening. Prevalence estimates of mammography by age and state were obtained through analysis of data from the Behavioral Risk Factor Surveillance System (BRFSS). The BRFSS is an ongoing system of surveys conducted by the state health departments in cooperation with the Centers for Disease Control and Prevention. Prevalence estimates of mammography by race/ethnicity, poverty, and other demographic factors are from the National Health Interview Survey.

Important note about estimated cases and deaths. The projected number of new cancer cases and deaths for the current year is model-based and may produce numbers that vary considerably from year to year. For this reason, we discourage the use of our estimates to track cancer trends. Incidence and mortality rates reported by SEER and NCHS are the conventional statistics used to tracking cancer incidence and mortality trends for the US. Rates from state cancer registries are useful for tracking local trends.

References


blood. breast cancer on Long Island. II. Organochlorine compound levels in
meta-analysis of the epidemiologic evidence. L. Dichlorodiphenyldichloroethane burden and breast cancer risk: a
140. Lopez-Cervantes M, Torres-Sanchez L, Tobias A, Lopez-Carrillo
chlorines as potential endocrine disruptors. Review of the etiology of breast cancer with special attention to organo
137. Hoover RN, Hyer M, Pfeiffer RM, et al. Adverse health outcomes in
135. Clemons M, Loijens L, Goss P. Breast cancer risk following irradia
134. Russo J, Hu YF, Yang X, Russo IH. Developmental, cellular, and molecu
133. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radio-
cancer and hormonal contraceptives: collaborative reanalysis of indivi-
dual data on 53,297 women with breast cancer and 100,239 women
130. Anderson LN, Cotterchio M, Mirea L, Ozcelik H, Kreiger N. Passive
129. Xue F, Willett WC, Rosner BA, Hankinson SE, Michels KB. Cigarette
128. Pirie K, Beral V, Peto R, Roddam A, Reeves G, Green J. Passive smok-
ing and breast cancer in never smokers: prospective study and meta-
127. US Department of Health and Human Services, The Health Consequences
of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon
126. DeRoo LA, Cummings P, Mueller BA. Smoking before the first preg-
and passive smoking with risk of breast cancer among postmenopausal
Active smoking and breast cancer risk: original cohort data and meta-
123. Steinland K, Whelan E, Deddens J, Stayner L, Ward E. Ethylene
oxide and breast cancer incidence in a cohort study of 7576 women
cancer? A systematic review and meta-analysis of epidemiological stud-
121. Fedele L, Tavani A, Negri E, et al. Alcohol consumption and breast
women exposed in utero to diethylstilbestrol. JAMA
119. Raynal P, Lachenal E, Gagliardi R, et al. Exposure to ethylene
oxide and breast cancer incidence in a cohort study of 7576 women
women given diethylstilbestrol (DES) during pregnancy. J Natl
115. Lavan DJ, Jr. Radiation effects on breast cancer risk: a pooled analysis of eight
114. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radio-
therapy and chemotherapy among young women with Hodgkin disease.
113. Russo J, Hu YF, Yang X, Russo IH. Developmental, cellular, and molecu-
112. Clemens M, Loijens L, Goss P. Breast cancer risk following irradiation
women given diethylstilbestrol (DES) during pregnancy. Br J Cancer.
110. Hoover RN, Hyer M, Pfeiffer RM, et al. Adverse health outcomes in
365(14):1304-14.
Review of the etiology of breast cancer with special attention to organo-
chlorines as potential endocrine disruptors. J Toxicol Environ Health B
108. Calle EE, Frumkin H, Henley SJ, Savitz DA, Thun MJ. Organochlorine
and breast cancer risk. CA Cancer J Clin. September/October 2002;
52(5):301-09.
107. Lopez-Cervantes M, Torres-Sanchez L, Tobias A, Lopez-Carrillo
L. Dichlorodiphenyldichloroethane burden and breast cancer risk: a
meta-analysis of the epidemiologic evidence. Environ Health Perspect.
106. Gammon MD, Wolff MS, Neugut AI, et al. Environmental toxins and
breast cancer on Long Island. II. Organochlorine compound levels in
109(S12):2667-711.
104. Couzin J. Cancer risk. Review rules out abortion-breast cancer link. Scien-
103. Takkouche B, Etmian M, Montes-Martinez A. Personal use of hair dyes
102. Mirick DK, Davis S, Thomas DB. Antiperspirant use and the risk of
101. Gikas PD, Mansfield L, Mokbel K. Do underarm cosmetics cause
100. Lipworth L, Tarone RE, Friis S, et al. Cancer among Scandinavian
women with cosmetic breast implants: a pooled long-term follow-up
Breast cancer following augmentation mammoplasty (United States).
98. US Food and Drug Administration. FDA Medical Device Safety
Communication: Reports of Anaplastic Large Cell Lymphoma (ALCL) in
97. Nelson HD, Smith ME, Griffin JC, Fu R. Use of medications to reduce
risk for primary breast cancer: a systematic review for the U.S. Preventive
tion of breast cancer: report of the National Surgical Adjuvant Breast
prophylaxis for breast cancer–96-month follow-up of the randomized
94. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the preven-
tion of breast cancer: current status of the National Surgical Adju-
on risk of breast cancer in postmenopausal women: results from the
MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
National Surgical Adjuvant Breast and Bowel Project Study of Tamoxi-
fen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer
tible breast cancer prediction test based on plasma samples from a
prospective cohort of middle-aged women: the Grip study. Cancer


We **save lives** and create more birthdays by helping you stay well, helping you get well, by finding cures, and by fighting back.

cancer.org  |  1.800.227.2345